APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 05
May 2006



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2006

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

Cumulative Supplement 05

May 2006

CONTENTS

PAGE

Note:
Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

CUMULATIVE SUPPLEMENT 05
May 2006

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
APOTEX CORP (APOTEX)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX CORP (APOTEX)	APOTEX INC RICHMOND HILL (APOTEX INC)

APOTEX INC (APOTEX)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX INC (APOTEX)	APOTEX INC RICHMOND HILL (APOTEX INC)
APOTEX INC (APOTEX INC)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX INC (APOTEX INC)	APOTEX INC RICHMOND HILL (APOTEX INC)
AVENTIS PHARMACEUTICALS INC (AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
AVENTIS PHARMACEUTICAL PRODUCTS INC (AVENTIS PHARMS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
CLAY PARK LABS INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
LOREX PHARMACEUTICALS (LOREX)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
MARTEC SCIENTIFIC INC (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
PRIVATE FORMULATIONS INC (PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC (PHARM FORM)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
SANKYO PHARMA INC (SANKYO)	DAIICHI SANKYO INC (DAIICHI SANKYO)
SANOFI AVENTIS US INC (SANOFI AVENTIS US)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI-AVENTIS US INC (SANOFI AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI INC (SANOFI)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC (SANOFI SYN RES)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
STERIS LABORATORIES INC (STERIS)	WATSON LABORATORIES INC (WATSON)
TRIGEN LABORATORIES INC (TRIGEN)	JUBILANT PHARMACEUTICALS INC (JUBILANT PHARMS)
UCB PHARMA INC (UCB PHARMA)	UCB INC (UCB INC)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2005	MAR 2006	SEP 2006	DEC 2006
DRUG PRODUCTS LISTED	11368	11487		
SINGLE SOURCE	2428	2461		
	(21.4%)	(21.4%)		
MULTISOURCE	8851	8937		
	(77.9%)	(77.8%)		
THERAPEUTICALLY EQUIVALENT	8642	8730		
	(76.04%)	(76.0%)		
NOT THERAPEUTICALLY EQUIVALENT	209	207		
	(1.8%)	(1.8%)		
EXCEPTIONS[1]	89	89		
	(0.8%)	(0.8%)		
NEW MOLECULAR ENTITIES APPROVED	11	6		
NUMBER OF APPLICANTS	628	629		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 ZOCOR (SIMVASTATIN) PATENT RELISTING

U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in *Ranbaxy Labs. v.Leavitt,* No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in *Approved Drug Products with Therapeutic Equivalence Ratings* until any applicable periods of exclusivity pursuant to section *505(j)(5)(B)(iv)* of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

SECTRAL

>A>	AB		DR REDDYS LABS INC	EQ 200MG BASE	N18917	001	Dec 28, 1984	May	CAHN
>A>	AB	+		EQ 400MG BASE	N18917	003	Dec 28, 1984	May	CAHN
>D>	AB		ESP PHARMA	EQ 200MG BASE	N18917	001	Dec 28, 1984	May	CAHN
>D>	AB	+		EQ 400MG BASE	N18917	003	Dec 28, 1984	May	CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

	AB	+	MIKART	650MG;50MG	N89988	001	Oct 26, 1992	Jan	CRLD

SEDAPAP

		@	MAYRAND	650MG;50MG	N88944	001	Oct 17, 1985	Jan	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@	CLONMEL	120MG/5ML;12MG/5ML	N40098	001	Sep 20, 1996	Jan	DISC

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA	+	TEVA	300MG;60MG	N88629	001	Mar 06, 1985	Apr	CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

>D> HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>D>		+	ENDO PHARMS	400MG;5MG	N40288	001	Nov 27, 1998	May	CTNA
>D>		+		400MG;7.5MG	N40288	002	Nov 27, 1998	May	CTNA
>D>		+		400MG;10MG	N40288	003	Nov 27, 1998	May	CTNA
		@		500MG;7.5MG	N40280	001	Sep 30, 1998	Feb	DISC
		@		650MG;7.5MG	N40280	002	Sep 30, 1998	Feb	DISC
		@		650MG;10MG	N40280	003	Sep 30, 1998	Feb	DISC
		@		750MG;7.5MG	N40281	002	Sep 30, 1998	Feb	DISC
			MIKART	300MG;5MG	N40658	001	Jan 19, 2006	Jan	NEWA
		+		300MG;7.5MG	N40556	002	Mar 24, 2006	Mar	NEWA
	AA		VINTAGE PHARMS	325MG;5MG	N40655	001	Jan 19, 2006	Jan	NEWA
	AA			325MG;7.5MG	N40656	001	Jan 19, 2006	Jan	NEWA

HY-PHEN

		@	ASCHER	500MG;5MG	N87677	001	May 03, 1982	Mar	DISC

>A> ZYDONE

>A>		+	ENDO PHARMS	400MG;5MG	N40288	001	Nov 27, 1998	May	CTNA
>A>		+		400MG;7.5MG	N40288	002	Nov 27, 1998	May	CTNA
>A>		+		400MG;10MG	N40288	003	Nov 27, 1998	May	CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>A>		+	MIKART	400MG;2.5MG	N40679	001	May 16, 2006	May	NEWA
		+		400MG;5MG	N40687	001	Apr 27, 2006	Apr	NEWA
		+		400MG;7.5MG	N40698	001	Apr 27, 2006	Apr	NEWA
		+		400MG;10MG	N40692	001	Apr 27, 2006	Apr	NEWA
				500MG;10MG	N40676	001	Apr 19, 2006	Apr	NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB	+	TARO	250MG	N40195	002	May 28, 1997	Mar	CRLD

DIAMOX

	@	DURAMED PHARMS BARR	125MG	N08943	001		Mar	DISC
	@		250MG	N08943	002		Mar	DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT		VINTAGE	2%;1%	N40609	001	Feb 06, 2006	Jan	NEWA

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

>D>	AB	AAIPHARMA LLC	200MG	N74833	001	Apr 22, 1997	May	CAHN
>A>	AB	CLONMEL HLTHCARE	200MG	N74833	001	Apr 22, 1997	May	CAHN

TABLET; ORAL

ACYCLOVIR

>D>	AB	AAIPHARMA LLC	400MG	N74946	001	Nov 19, 1997	May	CAHN
>D>	AB		800MG	N74946	002	Nov 19, 1997	May	CAHN
>A>	AB	CLONMEL HLTHCARE	400MG	N74946	001	Nov 19, 1997	May	CAHN
>A>	AB		800MG	N74946	002	Nov 19, 1997	May	CAHN

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

	@	GENPHARM	0.09MG/INH	N73045	001	Aug 19, 1997	Feb	DISC
	@	PLIVA	0.09MG/INH	N74072	001	Aug 01, 1996	Feb	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN		RXELITE	EQ 0.083% BASE	N77569	001	Apr 04, 2006	Mar	NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

	+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N21163	001	May 18, 2000	Jan	CAHN

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

	+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30UGM/ML	N21559	001	Jun 16, 2003	Jan	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB		MYLAN	0.5MG	N77391	002	Jan 26, 2006	Jan	NEWA
AB			1MG	N77391	003	Jan 26, 2006	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	MYLAN	2MG	N77391	004	Jan 26, 2006	Jan	NEWA
AB		3MG	N77391	001	Jan 26, 2006	Jan	NEWA

XANAX XR

AB	PHARMACIA AND UPJOHN	0.5MG	N21434	001	Jan 17, 2003	Jan	CFTG
AB		1MG	N21434	002	Jan 17, 2003	Jan	CFTG
AB		2MG	N21434	003	Jan 17, 2003	Jan	CFTG
AB +		3MG	N21434	004	Jan 17, 2003	Jan	CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	AMIDE PHARM	100MG	N77659	001	Feb 23, 2006	Feb	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

	NOVARTIS	EQ 5MG BASE;40MG	N20364	007	Apr 11, 2006	Apr	NEWA
		EQ 10MG BASE;20MG	N20364	005	Jun 20, 2002	Apr	CRLD
+		EQ 10MG BASE;40MG	N20364	006	Apr 11, 2006	Apr	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL
AMMONIUM LACTATE

AB	PADDOCK	EQ 12% BASE	N76829	001	Feb 07, 2006	Jan	NEWA

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	N62058	001		Jan	CAHN
AB		500MG	N62058	002		Jan	CAHN

FOR SUSPENSION; ORAL
AMOXICILLIN

AB	AM ANTIBIOTICS	125MG/5ML	N62059	001		Jan	CAHN
AB		250MG/5ML	N62059	002		Jan	CAHN

TABLET; ORAL
AMOXICILLIN

AB	HIKMA	875MG	N65255	001	Mar 29, 2006	Mar	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>D> AB	ABRIKA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472	001	Sep 30, 2003	May	CAHN
>D> AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472	002	Sep 30, 2003	May	CAHN
>D> AB		5MG;5MG;5MG;5MG	N40472	003	Sep 30, 2003	May	CAHN
>D> AB		7.5MG;7.5MG;7.5MG;7.5MG	N40472	004	Sep 30, 2003	May	CAHN
>A> AB	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472	001	Sep 30, 2003	May	CAHN
>A> AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472	002	Sep 30, 2003	May	CAHN
>A> AB		5MG;5MG;5MG;5MG	N40472	003	Sep 30, 2003	May	CAHN
>A> AB		7.5MG;7.5MG;7.5MG;7.5MG	N40472	004	Sep 30, 2003	May	CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@	AM ANTIBIOTICS	EQ 250MG BASE	N61602	001		Jan	CAHN
@		EQ 500MG BASE	N61602	002		Jan	CAHN

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601	001		Jan	CAHN
@		EQ 250MG BASE/5ML	N61601	002		Jan	CAHN

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+	VICURON	50MG/VIAL	N21632	001	Feb 17, 2006	Feb	NEWA

ANISINDIONE

TABLET; ORAL

MIRADON

@	SCHERING	50MG	N10909	003		Jan	DISC

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

SEPTOCAINE

	DEPROCO	4%;EQ 0.005MG BASE/ML	N22010	001	Mar 30, 2006	Mar	NEWA
+		4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971	001	Apr 03, 2000	Mar	CPOT

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML(4%; EQ 0.005MG BASE/ML)	N22010	001	Mar 30, 2006	Apr	CAIN
+		4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971	001	Apr 03, 2000	Apr	CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265	001	Feb 21, 2001	Jan	CAHN

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351	001	Mar 05, 1999	Feb	DISC

FIORINAL W/CODEINE

AB +	WATSON PHARMS	325MG;50MG;40MG;30MG	N19429	003	Oct 26, 1990	Apr	CTNA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

		TABLET; ORAL							
		PERCODAN-DEMI							
		@ ENDO PHARMS	325MG;2.25MG;0.19MG	N07337	005			Feb	DISC

ATOVAQUONE

>D>		TABLET; ORAL							
>D>		MEPRON							
>D>	+	GLAXOSMITHKLINE	250MG	N20259	001	Nov 25, 1992		May	DISC
>A>		@	250MG	N20259	001	Nov 25, 1992		May	DISC

BACAMPICILLIN HYDROCHLORIDE

		FOR SUSPENSION; ORAL							
		SPECTROBID							
		@ PFIZER	125MG/5ML	N50556	001	Mar 23, 1982		Feb	DISC
		TABLET; ORAL							
		SPECTROBID							
		@ PFIZER	400MG	N50520	001			Feb	DISC

BENAZEPRIL HYDROCHLORIDE

		TABLET; ORAL							
		BENAZEPRIL HYDROCHLORIDE							
AB		APOTEX INC	5MG	N77128	001	Mar 08, 2006		Feb	NEWA
AB			10MG	N77128	002	Mar 08, 2006		Feb	NEWA
AB			20MG	N77128	003	Mar 08, 2006		Feb	NEWA
AB			40MG	N77128	004	Mar 08, 2006		Feb	NEWA
AB		BIOKEY	5MG	N76820	001	Feb 03, 2006		Jan	NEWA
AB			10MG	N76820	002	Feb 03, 2006		Jan	NEWA
AB			20MG	N76820	003	Feb 03, 2006		Jan	NEWA
AB			40MG	N76820	004	Feb 03, 2006		Jan	NEWA

BENZPHETAMINE HYDROCHLORIDE

		TABLET; ORAL							
		BENZPHETAMINE HYDROCHLORIDE							
AA		PADDOCK	50MG	N40578	001	Apr 17, 2006		Apr	NEWA
		DIDREX							
AA	+	PHARMACIA AND UPJOHN	50MG	N12427	002			Apr	CFTG

BENZQUINAMIDE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		EMETE-CON							
		@ PFIZER	EQ 50MG BASE/VIAL	N16820	001			Mar	DISC

BETAINE, ANHYDROUS

		FOR SOLUTION; ORAL							
		CYSTADANE							
	+	JAZZ	1GM/SCOOPFUL	N20576	001	Oct 25, 1996		Feb	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

		OINTMENT; TOPICAL							
		TACLONEX							
	+	LEO PHARM PRODS	0.064%;0.005%	N21852	001	Jan 09, 2006		Jan	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

>D>		+	ALLERGAN	0.15%	N21262	001	Mar 16, 2001	May	CTEC
>A>	AT	+		0.15%	N21262	001	Mar 16, 2001	May	CTEC

BRIMONIDINE TARTRATE

	AT		AKORN	0.2%	N76439	001	Mar 14, 2006	Feb	NEWA
>A>	AT		ALCON RES	0.15%	N21764	001	May 22, 2006	May	NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

		+	ALCON	1%	N20816	001	Apr 01, 1998	Feb	CAHN

BUDESONIDE

SPRAY, METERED; NASAL

RHINOCORT

		+	ASTRAZENECA	0.032MG/INH	N20746	001	Oct 01, 1999	Mar	CRLD
		@		0.064MG/INH	N20746	002	Oct 01, 1999	Mar	DISC

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

	AP	+	BEDFORD	0.25MG/ML	N74441	001	Jan 27, 1995	Feb	CRLD

BUMEX

		@	ROCHE	0.25MG/ML	N18226	001	Feb 28, 1983	Feb	DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

		+	HOSPIRA	0.5%	N22046	002	Jul 13, 1983	Apr	NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

		+	HOSPIRA	0.5%;EQ 0.009MG BASE/ML	N22046	001	Jul 13, 1983	Apr	NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

	AB		APOTEX INC	75MG	N76143	001	Jan 17, 2006	Jan	NEWA
	AB			100MG	N76143	002	Jan 17, 2006	Jan	NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

		+	PDL BIOPHARMA INC	6MG/ML	N20954	001	Feb 04, 1999	Jan	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

		@	NOVARTIS	100MG;2MG	N09000	002		Feb	DISC

MIGERGOT

		+	G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CRLD

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX
+ LEO PHARM 0.005% N20554 001 Jul 22, 1996 Feb CAHN

OINTMENT; TOPICAL
DOVONEX
+ LEO PHARM 0.005% N20273 001 Dec 29, 1993 Feb CAHN

SOLUTION; TOPICAL
DOVONEX
+ LEO PHARM 0.005% N20611 001 Mar 03, 1997 Feb CAHN

CALCITONIN, SALMON

INJECTABLE; INJECTION
MIACALCIN
+ NOVARTIS 200 IU/ML N17808 002 Mar 29, 1991 Jan CTEC

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL
AB ROXANE 0.25UGM N76917 001 Mar 27, 2006 Mar NEWA

INJECTABLE; INJECTION
CALCITRIOL
AP GENIX THERAP 0.001MG/ML N77102 001 Feb 08, 2006 Jan NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND
>D> + ASTRAZENECA 8MG N20838 002 Jun 04, 1998 May CRLD
>A> 8MG N20838 002 Jun 04, 1998 May CRLD

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL
@ CLONMEL HLTHCARE 12.5MG N74423 001 Feb 13, 1996 Jan DISC
@ 25MG N74423 002 Feb 13, 1996 Jan DISC
@ 50MG N74423 003 Feb 13, 1996 Jan DISC
@ 100MG N74423 004 Feb 13, 1996 Jan DISC
@ ENDO LABS 12.5MG N74418 001 Feb 13, 1996 Feb DISC
@ 25MG N74418 002 Feb 13, 1996 Feb DISC
@ 50MG N74418 003 Feb 13, 1996 Feb DISC
@ 100MG N74418 004 Feb 13, 1996 Feb DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE
@ ENDO LABS 25MG;15MG N74788 001 Dec 29, 1997 Feb DISC
@ 25MG;25MG N74788 002 Dec 29, 1997 Feb DISC
@ 50MG;15MG N74788 004 Dec 29, 1997 Feb DISC
@ 50MG;25MG N74788 003 Dec 29, 1997 Feb DISC

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN
AP WATSON LABS 50MG/VIAL N77383 001 Jan 27, 2006 Jan NEWA

			INJECTABLE; INJECTION						
			CARBOPLATIN						
	AP		WATSON LABS	150MG/VIAL	N77383	002	Jan 27, 2006	Jan	NEWA
	AP			450MG/VIAL	N77383	003	Jan 27, 2006	Jan	NEWA
			INJECTABLE; IV (INFUSION)						
			CARBOPLATIN						
		@	AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247	001	Oct 21, 2004	Feb	DISC
	AP			EQ 50MG/5ML (10MG/ML)	N77266	001	Feb 15, 2006	Jan	NEWA
		@		EQ 150MG/15ML (10MG/ML)	N77247	002	Oct 21, 2004	Feb	DISC
	AP			EQ 150MG/15ML (10MG/ML)	N77266	002	Feb 15, 2006	Jan	NEWA
	AP			EQ 450MG/45ML (10MG/ML)	N77266	003	Feb 15, 2006	Jan	NEWA
	AP			EQ 600MG/60ML (10MG/ML)	N77266	004	Feb 15, 2006	Jan	NEWA
	AP		BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244	004	Jan 20, 2006	Jan	NEWA
			CASPOFUNGIN ACETATE						
			INJECTABLE; IV (INFUSION)						
			CANCIDAS						
>A>		+	MERCK	50MG/VIAL	N21227	001	Jan 26, 2001	May	CAHN
>A>		+		70MG/VIAL	N21227	002	Jan 26, 2001	May	CAHN
>D>		+	MERCK RES	50MG/VIAL	N21227	001	Jan 26, 2001	May	CAHN
>D>		+		70MG/VIAL	N21227	002	Jan 26, 2001	May	CAHN
			CEFACLOR						
			TABLET, EXTENDED RELEASE; ORAL						
			CEFACLOR						
>D>	AB	+	IVAX PHARMS	EQ 500MG BASE	N65057	001	Jan 05, 2001	May	CAHN
>A>	AB	+	PAR PHARM	EQ 500MG BASE	N65057	001	Jan 05, 2001	May	CAHN
			CEFADROXIL/CEFADROXIL HEMIHYDRATE						
			CAPSULE; ORAL						
			CEFADROXIL						
	AB	+	IVAX PHARMS	EQ 500MG BASE	N62766	001	Mar 03, 1987	Mar	CRLD
	AB		TEVA PHARMS	EQ 500MG BASE	N65282	001	Jan 20, 2006	Jan	NEWA
	AB		WESTWARD	EQ 500MG BASE	N65311	001	Feb 07, 2006	Jan	NEWA
			DURICEF						
		@	WARNER CHILCOTT	EQ 500MG BASE	N50512	001		Jan	DISC
			FOR SUSPENSION; ORAL						
			CEFADROXIL						
			RANBAXY	EQ 125MG BASE/5ML	N65115	001	Mar 26, 2003	Feb	CTEC
	AB		TEVA PHARMS	EQ 250MG BASE/5ML	N65278	001	Jan 20, 2006	Jan	NEWA
	AB			EQ 500MG BASE/5ML	N65278	002	Jan 20, 2006	Jan	NEWA
			DURICEF						
		@	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527	002		Feb	DISC
			TABLET; ORAL						
			CEFADROXIL						
	AB		HIKMA	EQ 1GM BASE	N65260	001	Mar 30, 2006	Mar	NEWA
	AB	+	IVAX PHARMS	EQ 1GM BASE	N62774	001	Apr 08, 1987	Feb	CRLD
			DURICEF						
		@	WARNER CHILCOTT	EQ 1GM BASE	N50528	001		Jan	DISC
			CEFAZOLIN SODIUM						
			INJECTABLE; INJECTION						
			CEFAZOLIN AND DEXTROSE						
>D>		+	B BRAUN	EQ 500MG BASE/VIAL	N50779	001	Jul 27, 2000	May	DISC
>A>		@		EQ 500MG BASE/VIAL	N50779	001	Jul 27, 2000	May	DISC

CEFDINIR

CAPSULE; ORAL

>A>		CEFDINIR						
>A>	AB	LUPIN	300MG	N65264	001	May 19, 2006	May	NEWA
		OMNICEF						
>D>	+	ABBOTT	300MG	N50739	001	Dec 04, 1997	May	CFTG
>A>	AB +		300MG	N50739	001	Dec 04, 1997	May	CFTG

FOR SUSPENSION; ORAL

>A>		CEFDINIR						
>A>	AB	LUPIN (USA)	125MG/5ML	N65259	001	May 31, 2006	May	NEWA
		OMNICEF						
>D>		ABBOTT	125MG/5ML	N50749	001	Dec 04, 1997	May	CFTG
>A>	AB		125MG/5ML	N50749	001	Dec 04, 1997	May	CFTG

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

>D>		CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER						
>D>	+	B BRAUN	EQ 2GM BASE	N50792	001	Jul 29, 2004	May	DISC
>A>	@		EQ 2GM BASE	N50792	001	Jul 29, 2004	May	DISC
>D>		CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER						
>D>	+	B BRAUN	EQ 1GM BASE	N50792	002	Jul 29, 2004	May	DISC
>A>	@		EQ 1GM BASE	N50792	002	Jul 29, 2004	May	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

		CEFOXITIN						
AP		ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313	001	Jan 23, 2006	Jan	NEWA
AP			EQ 2GM BASE/VIAL	N65313	002	Jan 23, 2006	Jan	NEWA
AP			EQ 10GM BASE/VIAL	N65312	001	Feb 13, 2006	Jan	NEWA
		CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER						
AP		B BRAUN	EQ 1GM BASE/VIAL	N65214	001	Mar 10, 2006	Feb	NEWA
AP			EQ 2GM BASE/VIAL	N65214	002	Mar 10, 2006	Feb	NEWA

>D> CEFTAZIDIME (ARGININE FORMULATION)

>D> INJECTABLE; INJECTION

>D>		CEPTAZ						
>D>	+	GLAXOSMITHKLINE	1GM/VIAL	N50646	002	Sep 27, 1990	May	DISC
>A>	@		1GM/VIAL	N50646	002	Sep 27, 1990	May	DISC
>D>	+		2GM/VIAL	N50646	003	Sep 27, 1990	May	DISC
>A>	@		2GM/VIAL	N50646	003	Sep 27, 1990	May	DISC
>D>	+		10GM/VIAL	N50646	004	Sep 27, 1990	May	DISC
>A>	@		10GM/VIAL	N50646	004	Sep 27, 1990	May	DISC

CEFTRIAXONE

INJECTABLE; INJECTION

		CEFTRIAXONE						
AP		TEVA	EQ 10GM BASE/VIAL	N65274	001	May 01, 2006	Apr	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

		CEFTRIAXONE						
AP		AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245	001	Feb 15, 2006	Jan	NEWA
AP			EQ 500MG BASE/VIAL	N65245	002	Feb 15, 2006	Jan	NEWA
AP			EQ 1GM BASE/VIAL	N65245	003	Feb 15, 2006	Jan	NEWA

INJECTABLE; IM-IV
CEFTRIAXONE

	AP	AM PHARM PARTNERS	EQ 2GM BASE/VIAL	N65245	004	Feb 15, 2006	Jan	NEWA

INJECTABLE; INJECTION
CEFTRIAXONE

	AP	AM PHARM	EQ 10GM BASE/VIAL	N65252	001	Feb 15, 2006	Jan	NEWA
>A>	AP	WOCKHARDT	EQ 1GM BASE/VIAL	N65180	001	May 12, 2006	May	NEWA

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

	AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308	001	Mar 29, 2006	Mar	NEWA
	AB		EQ 250MG BASE	N65308	002	Mar 29, 2006	Mar	NEWA
	AB		EQ 500MG BASE	N65308	003	Mar 29, 2006	Mar	NEWA

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

	AB	HIKMA	EQ 250MG BASE	N65215	001	Jan 24, 2006	Jan	NEWA
	AB		EQ 500MG BASE	N65215	002	Jan 24, 2006	Jan	NEWA

KEFLEX

>A>		ADVANCIS PHARM	EQ 333MG BASE	N50405	004	May 12, 2006	May	NEWA
>D>	AB	+	EQ 500MG BASE	N50405	003		May	CRLD
>A>	AB		EQ 500MG BASE	N50405	003		May	CRLD
>A>		+	EQ 750MG BASE	N50405	005	May 12, 2006	May	NEWA

CEPHRADINE

CAPSULE; ORAL
ANSPOR

		@ GLAXOSMITHKLINE	250MG	N61859	001		Mar	DISC
		@	500MG	N61859	002		Mar	DISC

>D> CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

>D> FOR SUSPENSION; INTRATRACHEAL
>D> EXOSURF NEONATAL

>D>		+ GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N20044	001	Aug 02, 1990	May	DISC
>A>		@	12MG/VIAL;108MG/VIAL;8MG/VIAL	N20044	001	Aug 02, 1990	May	DISC

>D> CHLORPROMAZINE

>D> SUPPOSITORY; RECTAL
>D> THORAZINE

>D>		+ GLAXOSMITHKLINE	25MG	N09149	024		May	DISC
>A>		@	25MG	N09149	024		May	DISC
>D>		+	100MG	N09149	033		May	DISC
>A>		@	100MG	N09149	033		May	DISC

CHLORPROMAZINE HYDROCHLORIDE

>D> CAPSULE, EXTENDED RELEASE; ORAL
>D> THORAZINE

>D>		+ GLAXOSMITHKLINE	200MG	N11120	019		May	DISC
>A>		@	200MG	N11120	019		May	DISC
>D>		+	300MG	N11120	020		May	DISC
>A>		@	300MG	N11120	020		May	DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	PERRIGO	0.77%	N77364	001	Mar 03, 2006	Mar	CAHN
AB	PERRIGO NEW YORK	0.77%	N77364	001	Mar 03, 2006	Feb	NEWA

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	MUTUAL PHARM	50MG	N77208	002	Mar 29, 2006	Mar	NEWA
AB		100MG	N77208	001	Mar 29, 2006	Mar	NEWA
AB	MYLAN	50MG	N77323	002	Apr 20, 2006	Apr	NEWA
AB		100MG	N77323	001	Apr 20, 2006	Apr	NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	@ ENDO PHARMS	200MG	N74281	001	May 17, 1994	Feb	DISC
	@	300MG	N74281	002	May 17, 1994	Feb	DISC
	@	400MG	N74281	003	May 17, 1994	Feb	DISC
	@	800MG	N74329	001	May 17, 1994	Feb	DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

	@ ENDO PHARMS	EQ 300MG BASE/2ML	N74005	001	Aug 31, 1994	Feb	DISC

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

	@ ENDO PHARMS	EQ 300MG BASE/5ML	N74251	001	Dec 22, 1994	Feb	DISC

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

>A>	AA	SILARX	EQ 10MG BASE/5ML	N77629	001	Jun 15, 2006	May	NEWA

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

	AB	TARO	EQ 10MG BASE	N77278	001	Mar 22, 2006	Mar	NEWA
	AB		EQ 20MG BASE	N77278	002	Mar 22, 2006	Mar	NEWA
	AB		EQ 40MG BASE	N77278	003	Mar 22, 2006	Mar	NEWA
	AB	TEVA PHARMS	EQ 10MG BASE	N77213	001	Mar 31, 2006	Mar	NEWA
	AB		EQ 20MG BASE	N77213	002	Mar 31, 2006	Mar	NEWA
	AB		EQ 40MG BASE	N77213	003	Mar 31, 2006	Mar	NEWA

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>A>	AB	WOCKHARDT	250MG	N65266	001	May 31, 2006	May	NEWA
>A>	AB		500MG	N65266	002	May 31, 2006	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

	+	RANBAXY	1GM	N65210	001	Jan 26, 2005	Apr	CRLD

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	ALTANA	EQ 1% BASE	N65254	001	Feb 14, 2006	Jan	NEWA

CLOBETASOL PROPIONATE

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

>D> AT	ALTANA	0.05%	N75391	001	Feb 08, 1999	May	DISC
>A>	@	0.05%	N75391	001	Feb 08, 1999	May	DISC

SPRAY; TOPICAL
CLOBEX

+	GALDERMA LABS LP	0.05%	N21835	001	Oct 27, 2005	Feb	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE

AB	APOTEX	EQ 75MG BASE	N76274	001	Jan 20, 2006	Jan	NEWA

PLAVIX

AB +	SANOFI SYNTHELABO	EQ 75MG BASE	N20839	001	Nov 17, 1997	Jan	CFTG

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH VC W/ CODEINE

+	ALPHARMA US PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764	001	Oct 31, 1984	Jan	CTEC

PROMETHAZINE VC W/ CODEINE

@	MORTON GROVE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88896	001	Jan 04, 1985	Jan	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE WITH CODEINE SYRUP

AA	VINTAGE	10MG/5ML;6.25MG/5ML	N40650	001	Jan 31, 2006	Jan	NEWA

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
COLESTID

AB	PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N17563	003	Sep 22, 1995	Apr	CFTG
AB +		5GM/PACKET	N17563	004	Sep 22, 1995	Apr	CFTG

COLESTIPOL HYDROCHLORIDE

AB	IMPAX LABS	5GM/PACKET	N77277	002	May 02, 2006	Apr	NEWA
AB		5GM/SCOOPFUL	N77277	001	May 02, 2006	Apr	NEWA

FLAVORED COLESTID

	PHARMACIA AND UPJOHN	5GM/PACKET	N17563	001		Apr	CRLD

CROMOLYN SODIUM

>A> CONCENTRATE; ORAL
>A> GASTROCROM

>A> +	AZUR PHARMA	100MG/5ML	N20479	001	Feb 29, 1996	May	CDFR

>D> SOLUTION, CONCENTRATE; ORAL
>D> GASTROCROM

>D> +	AZUR PHARMA	100MG/5ML	N20479	001	Feb 29, 1996	May	CDFR
+		100MG/5ML	N20479	001	Feb 29, 1996	Feb	CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL

		NASCOBAL						
		@ QOL MEDCL	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

		CYCL0BENZAPRINE HYDROCHLORIDE						
AB		JUBILANT PHARMS	5MG	N77563	001	Apr 19, 2006	Apr	NEWA
AB			10MG	N77563	002	Apr 19, 2006	Apr	NEWA
		CYCLOBENZAPRINE HYDROCHLORIDE						
AB		AMIDE PHARM	5MG	N77291	001	Feb 03, 2006	Jan	NEWA
AB		MUTUAL PHARM	5MG	N73541	002	Apr 06, 2006	Mar	NEWA
AB		MYLAN	5MG	N73144	002	Feb 03, 2006	Jan	NEWA
AB		SANDOZ	5MG	N72854	002	Feb 03, 2006	Jan	NEWA
AB		WATSON LABS	5MG	N71611	002	Feb 03, 2006	Jan	NEWA
			7.5MG	N71611	003	Feb 03, 2006	Jan	NEWA
		FLEXERIL						
AB		MCNEIL CONS SPECLT	5MG	N17821	001		Jan	CFTG

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HYDROCHLORIDE						
>D>		@ ABC HOLDING	4MG	N88212	001	May 26, 1983	May	CAHN
>A>		@ TG UNITED LABS	4MG	N88212	001	May 26, 1983	May	CAHN
		CYPROHEPTADINE HYDROCLORIDE						
>A>	AA	STASON PHARMS	4MG	N40644	001	May 30, 2006	May	NEWA

>A> DECITABINE

>A> INJECTABLE; INTRAVENOUS

>A>		DACOGEN						
>A>	+	MGI PHARMA INC	50MG/VIAL	N21790	001	May 02, 2006	May	NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

		DEFEROXAMINE MESYLATE						
AP		SICOR PHARMS	500MG/VIAL	N76806	001	Mar 31, 2006	Mar	NEWA
AP			2GM/VIAL	N76806	002	Mar 31, 2006	Mar	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

		DECLOMYCIN						
		@ GLADES PHARMS LLC	75MG	N50261	001		Mar	CAHN
AB			150MG	N50261	002		Mar	CAHN
AB	+		300MG	N50261	003		Mar	CAHN
		@ PROTEIN DESIGN LABS	75MG	N50261	001		Feb	CAHN
AB			150MG	N50261	002		Feb	CAHN
AB	+		300MG	N50261	003		Feb	CAHN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

		CLARINEX-D 12 HOUR						
	+	SCHERING	2.5MG;120MG	N21313	001	Feb 01, 2006	Feb	NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

		@ BEDFORD	0.004MG/ML	N74575	001	Feb 18, 2000	Jan	DISC

DESMOPRESSIN ACETATE PRESERVATIVE FREE

		@ BEDFORD	0.004MG/ML	N74574	001	Feb 18, 2000	Jan	DISC

TABLET; ORAL
DESMOPRESSIN ACETATE

AB		APOTEX	0.1MG	N77414	001	Mar 07, 2006	Feb	NEWA
AB			0.2MG	N77414	002	Mar 07, 2006	Feb	NEWA
AB		TEVA PHARMS	0.1MG	N77122	001	Jan 25, 2006	Jan	NEWA
AB			0.2MG	N77122	002	Jan 25, 2006	Jan	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

AB	+	DURAMED	0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN
AB	+		0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE

AP		BAXTER HLTHCARE	EQ 10MG PHOSPHATE/ML	N87702	001	Sep 07, 1982	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

		@ ENDO PHARMS	5MG	N40299	001	May 13, 1999	Feb	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE DM

AA		VINTAGE	15MG/5ML;6.25MG/5ML	N40649	001	Feb 14, 2006	Jan	NEWA

DIAZEPAM

TABLET; ORAL
DIAZEPAM

AB		VINTAGE PHARMS	2MG	N77749	001	Mar 31, 2006	Mar	NEWA
AB			5MG	N77749	002	Mar 31, 2006	Mar	NEWA
AB			10MG	N77749	003	Mar 31, 2006	Mar	NEWA

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM

>D>	AB	+	SANDOZ	75MG	N74394	001	Nov 30, 1995	May	CRLD
>A>	AB			75MG	N74394	001	Nov 30, 1995	May	CRLD

VOLTAREN

>D>			@ NOVARTIS	75MG	N19201	003	Jul 28, 1988	May	CMFD
>A>	AB	+		75MG	N19201	003	Jul 28, 1988	May	CMFD

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HYDROCHLORIDE

>D>		@ ABC HOLDING	25MG	N88267	001	Aug 25, 1983	May	CAHN

TABLET; ORAL
DIETHYLPROPION HYDROCHLORIDE

>D>	@ ABC HOLDING	25MG	N88268	001	Aug 25, 1983	May	CAHN
>A>	@ TG UNITED LABS	25MG	N88267	001	Aug 25, 1983	May	CAHN
>A>	@	25MG	N88268	001	Aug 25, 1983	May	CAHN

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

BX	+ ALTANA	0.05%	N76263	001	Dec 20, 2002	Jan	CRLD

FLORONE

	@ PHARMACIA AND UPJOHN	0.05%	N17741	001		Jan	DISC

FLORONE E

	@ PHARMACIA AND UPJOHN	0.05%	N19259	001	Aug 28, 1985	Jan	DISC

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

AB	+ TARO	0.05%	N75331	001	May 14, 1999	Jan	CRLD

FLORONE

	@ PHARMACIA AND UPJOHN	0.05%	N17994	001		Jan	DISC

PSORCON

	@ PHARMACIA AND UPJOHN	0.05%	N19260	001	Aug 28, 1985	Jan	DISC

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

AP	SANDOZ	0.25MG/ML	N40481	001	Aug 21, 2003	Jan	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTZAC

AB4	APOTEX INC	120MG	N76395	001	Feb 01, 2006	Jan	NEWA
AB4		180MG	N76395	002	Feb 01, 2006	Jan	NEWA
AB4		240MG	N76395	003	Feb 01, 2006	Jan	NEWA
AB4		300MG	N76395	004	Feb 01, 2006	Jan	NEWA
AB4		360MG	N76395	005	Feb 01, 2006	Jan	NEWA

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	AMIDE PHARM	25MG	N40542	001	Apr 21, 2006	Apr	NEWA
AB		50MG	N40542	002	Apr 21, 2006	Apr	NEWA
AB		75MG	N40542	003	Apr 21, 2006	Apr	NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

	@ IVAX PHARMS	EQ 100MG BASE	N70186	001	Nov 18, 1985	Jan	DISC
	@	EQ 150MG BASE	N70187	001	Nov 18, 1985	Jan	DISC
	@ SANDOZ	EQ 100MG BASE	N70470	001	Dec 10, 1985	Jan	DISC
	@	EQ 150MG BASE	N70471	001	Dec 10, 1985	Jan	DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION
ANZEMET

	+ SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624	002	Sep 11, 1997	Mar	CAIN

		INJECTABLE; INJECTION							
		ANZEMET							
	+	SANOFI AVENTIS US	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624	001	Sep 11, 1997	Mar	CAIN
	+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624	003	Dec 11, 2001	Mar	CAIN
		TABLET; ORAL							
		ANZEMET							
		SANOFI AVENTIS US	EQ 50MG BASE	N20623	001	Sep 11, 1997	Mar	CAIN
	+		EQ 100MG BASE	N20623	002	Sep 11, 1997	Mar	CAIN
		DOPAMINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		DOPAMINE HYDROCHLORIDE							
	@	HOSPIRA	40MG/ML	N74403	001	May 23, 1996	Apr	DISC
	@	INTL MEDICATION	40MG/ML	N18014	001		Apr	DISC
	@	SICOR PHARMS	40MG/ML	N72999	001	Oct 23, 1991	Apr	DISC
	@		80MG/ML	N73000	001	Oct 23, 1991	Apr	DISC
		DOXYCYCLINE							
		CAPSULE; ORAL							
		DOXYCYCLINE							
	@	PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	DISC
	@		EQ 150MG BASE	N65055	003	Jul 15, 2005	Mar	DISC
		RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC
>A>		CAPSULE, DELAYED RELEASE; ORAL							
>A>		ORACEA							
>A>	+	COLLAGENEX PHARMS	40MG	N50805	001	May 26, 2006	May	NEWA
		TABLET; ORAL							
		DOXYCYCLINE							
>D>		PAR PHARM	EQ 75MG BASE	N65070	003	Dec 30, 2002	May	CFTG
>A>	AB		EQ 75MG BASE	N65070	003	Dec 30, 2002	May	CFTG
			EQ 75MG BASE	N65070	003	Dec 30, 2002	Mar	CMFD
>A>	AB	RANBAXY	EQ 50MG BASE	N65356	001	May 31, 2006	May	NEWA
>A>	AB		EQ 75MG BASE	N65356	002	May 31, 2006	May	NEWA
>A>	AB		EQ 100MG BASE	N65356	003	May 31, 2006	May	NEWA
		DOXYCYCLINE HYCLATE							
		CAPSULE, DELAYED RELEASE; ORAL							
		DORYX							
	@	FH FAULDING CO LTD	EQ 75MG BASE	N50582	002	Aug 13, 2001	Apr	DISC
	@		EQ 100MG BASE	N50582	001	Jul 22, 1985	Apr	DISC
	@	WARNER CHILCOTT	EQ 100MG BASE	N62653	001	Oct 30, 1985	Apr	DISC
		DOXYCYCLINE HYCLATE							
		SANDOZ	EQ 75MG BASE	N65281	001	Dec 21, 2005	Apr	CTEC
	+		EQ 100MG BASE	N65281	002	Dec 21, 2005	Apr	CRLD
		TABLET; ORAL							
		DOXYCYCLINE HYCLATE							
	AB	PAR PHARM	EQ 20MG BASE	N65287	001	Feb 28, 2006	Feb	NEWA
		DROSPIRENONE; ETHINYL ESTRADIOL							
		TABLET; ORAL							
		YAZ							
	+	BERLEX LABS	3MG;0.02MG	N21676	001	Mar 16, 2006	Mar	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE

	+	DENTSPLY PHARM	0.02MG/ML;2%	N21381	002		Mar	CRLD

>D> PATCH; IONTOPHORESIS
>D> LIDOSITE TOPICAL SYSTEM KIT

>D>	+	VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504	001	May 06, 2004	May	CDFR

>A> PATCH; IONTOPHORESIS, TOPICAL
>A> LIDOSITE TOPICAL SYSTEM KIT

>A>	+	VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504	001	May 06, 2004	May	CDFR

>D> SOLUTION; IONTOPHORESIS
>D> LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D>	+	EMPI	0.01MG/ML;2%	N21486	001	Oct 26, 2004	May	CDFR

>A> SOLUTION; IONTOPHORESIS, TOPICAL
>A> LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>A>	+	EMPI	0.01MG/ML;2%	N21486	001	Oct 26, 2004	May	CDFR

ERYTHROMYCIN

SOLUTION; TOPICAL
A/T/S

AT		TARO PHARMS NORTH	2%	N62405	001	Nov 18, 1982	Feb	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL
>A> ESCITALOPRAM OXALATE

>A>	AB	IVAX PHARMS	5MG	N76765	001	May 22, 2006	May	NEWA
>A>	AB		10MG	N76765	002	May 22, 2006	May	NEWA
>A>	AB		20MG	N76765	003	May 22, 2006	May	NEWA

LEXAPRO

>D>		FOREST LABS	5MG	N21323	001	Aug 14, 2002	May	CFTG
>A>	AB		5MG	N21323	001	Aug 14, 2002	May	CFTG
>D>			10MG	N21323	002	Aug 14, 2002	May	CFTG
>A>	AB		10MG	N21323	002	Aug 14, 2002	May	CFTG
>D>	+		20MG	N21323	003	Aug 14, 2002	May	CFTG
>A>	AB +		20MG	N21323	003	Aug 14, 2002	May	CFTG

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

AB		PAR PHARM	1MG	N74826	001	Jul 03, 1997	Apr	CAHN
AB			2MG	N74826	002	Jul 03, 1997	Apr	CAHN

ESTRADIOL

GEL; TOPICAL
ESTROGEL

	@	ASCEND	0.06%	N21166	001	Feb 09, 2004	Jan	CAHN

GEL, METERED; TOPICAL
ESTROGEL

	+	ASCEND	0.06%	N21166	002	Feb 09, 2004	Jan	CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL
ESTRASORB

	+	ESPRIT PHARMA	0.25%	N21371	001	Oct 09, 2003	Feb	CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL
ENJUVIA
DURAMED 0.3MG N21443 001 Dec 20, 2004 Mar CMFD
0.45MG N21443 002 Dec 20, 2004 Mar CMFD
0.625MG N21443 003 May 10, 2004 Mar CMFD
\+ 1.25MG N21443 004 May 10, 2004 Mar CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

>A> TABLET; ORAL
>A> SEASONIQUE
>A> + DURAMED RES 0.03MG,0.01MG;0.15MG,N/A N21840 001 May 25, 2006 May NEWA

TABLET; ORAL-28
LEVONORGESTREL AND ETHINYL ESTRADIOL
>A> AB2 WATSON LABS 0.02MG;0.1MG N77681 001 May 31, 2006 May NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BALZIVA-21
BARR 0.035MG;0.4MG N76198 001 Apr 22, 2004 Mar CRLD

TABLET; ORAL-28
OVCON-35
AB + WARNER CHILCOTT 0.035MG;0.4MG N17716 001 Mar CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
LOESTRIN 24 FE
\+ WARNER CHILCOTT 0.02MG;1MG N21871 001 Feb 17, 2006 Feb NEWA

ETODOLAC

CAPSULE; ORAL
ETODOLAC
@ ENDO PHARMS 200MG N74842 001 Jul 17, 1997 Feb DISC
@ 300MG N74842 002 Jul 17, 1997 Feb DISC
AB + TARO 300MG N75078 002 Apr 30, 1998 Mar CRLD
LODINE
@ WYETH PHARMS INC 300MG N18922 003 Jan 31, 1991 Mar DISC

TABLET; ORAL
ETODOLAC
@ ENDO PHARMS 400MG N74841 001 Jun 27, 1997 Feb DISC

FENOFIBRATE

CAPSULE; ORAL
LIPOFEN
CIPHER 50MG N21612 001 Jan 11, 2006 Jan NEWA
100MG N21612 002 Jan 11, 2006 Jan NEWA
\+ 150MG N21612 003 Jan 11, 2006 Jan NEWA

TABLET; ORAL
FENOFIBRATE
AB + TEVA 160MG N76433 002 May 13, 2005 Jan CRLD
TRICOR
@ ABBOTT 54MG N21203 001 Sep 04, 2001 Jan DISC
@ 160MG N21203 003 Sep 04, 2001 Jan DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
FENOLDOPAM MESYLATE

AP	SANDOZ	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan	CAHN

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM

@	CLONMEL HLTHCARE	EQ 600MG BASE	N72326	001	Aug 17, 1988	Jan	DISC

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL
ACTIQ (SUGAR-FREE)

	CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Mar	CTNA
+		EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Mar	CTNA
		EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Mar	CTNA
		EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Mar	CTNA
		EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Mar	CTNA
		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Mar	CTNA

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL
IONSYS .

+	ALZA	10.8UGM	N21338	001	May 22, 2006	May	NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	30MG	N76502	001	Apr 11, 2006	Mar	NEWA
AB		60MG	N76502	002	Apr 11, 2006	Mar	NEWA
AB		180MG	N76502	003	Apr 11, 2006	Mar	NEWA

FLUCONAZOLE

TABLET; ORAL
FLUCONAZOLE

AB	GLENMARK PHARMA	50MG	N77253	001	Jan 25, 2006	Jan	NEWA
AB		100MG	N77253	002	Jan 25, 2006	Jan	NEWA
AB		150MG	N77253	003	Jan 25, 2006	Jan	NEWA
AB		200MG	N77253	004	Jan 25, 2006	Jan	NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

AP	SANDOZ	1MG/10ML (0.1MG/ML)	N77071	002	May 03, 2005	Jan	CAHN
AP		0.5MG/5ML (0.1MG/ML)	N77071	001	May 03, 2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROSPAN HFA

+	FOREST LABS	EQ 78UGM BASE/INH	N21247	001	Jan 27, 2006	Jan	NEWA

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

>A>		+	ALCON	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980	001	Mar 28, 2006	May	CAHN
>D>		+	ALCON RES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980	001	Mar 28, 2006	May	CAHN
		+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980	001	Mar 28, 2006	Mar	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

	AP	+	SICOR PHARMS	50MG/ML	N40023	001	Oct 18, 1991	Mar	CRLD

FLUOROURACIL

	AP	+	AM PHARM PARTNERS	50MG/ML	N40278	001	Sep 30, 1998	Mar	CRLD
	AP	+		50MG/ML	N40279	001	Sep 30, 1998	Mar	CRLD
	AP	+		50MG/ML	N40291	001	Mar 24, 1999	Mar	CRLD
	AP	+		50MG/ML	N40379	001	Nov 15, 2000	Mar	CRLD
			@ BEDFORD	50MG/ML	N89508	001	Jan 26, 1988	Apr	DISC
	AP	+		50MG/ML	N89508	001	Jan 26, 1988	Mar	CRLD
	AP	+	SICOR PHARMS	50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
	AP	+		50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
	AP	+	STERIS	50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD
			@ WATSON LABS	50MG/ML	N87792	001	Oct 13, 1982	Apr	DISC

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

SARAFEM

>A>			WARNER CHILCOTT	EQ 10MG BASE	N21860	001	May 19, 2006	May	NEWA
>A>				EQ 15MG BASE	N21860	002	May 19, 2006	May	NEWA
>A>		+		EQ 20MG BASE	N21860	003	May 19, 2006	May	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

		+	PHARM ASSOC	2.5MG/5ML	N40146	001	Aug 21, 1996	Apr	CRLD
			@ TEVA PHARMS	2.5MG/5ML	N81310	001	Apr 29, 1993	Apr	DISC

PROLIXIN

			@ APOTHECON	2.5MG/5ML	N12145	003		Apr	DISC

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

>D>									
>D>	AB	+	SCHERING	125MG	N18554	001	Jan 27, 1989	May	DISC
>A>			@	125MG	N18554	001	Jan 27, 1989	May	DISC

FLUTAMIDE

	AB		PAR PHARM	125MG	N75298	001	Sep 18, 2001	Apr	CAHN
>D>	AB		SANDOZ	125MG	N75818	001	Sep 18, 2001	May	CRLD
>A>	AB	+		125MG	N75818	001	Sep 18, 2001	May	CRLD

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

	AB		G AND W LABS	0.005%	N77168	001	Mar 03, 2006	Feb	NEWA

SPRAY, METERED; NASAL
FLONASE

AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19, 1994	Feb	CFTG

FLUTICASONE PROPIONATE

AB		ROXANE	0.05MG/SPRAY	N76504	001	Feb 22, 2006	Feb	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

AB		CARACO	25MG	N75900	001	Feb 23, 2006	Feb	NEWA
AB			50MG	N75900	002	Feb 23, 2006	Feb	NEWA
AB			100MG	N75900	003	Feb 23, 2006	Feb	NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCARNET SODIUM

AP		HOSPIRA	2.4GM/100ML	N77174	001	May 31, 2005	Feb	CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB		SANDOZ	100MG	N75428	001	Jan 24, 2006	Jan	NEWA
AB			300MG	N75428	002	Jan 24, 2006	Jan	NEWA
AB			400MG	N75428	003	Jan 24, 2006	Jan	NEWA

TABLET; ORAL
GABAPENTIN

AB		SANDOZ	600MG	N76120	001	Jan 27, 2006	Jan	NEWA
AB			800MG	N76120	002	Jan 27, 2006	Jan	NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION
OPTIMARK

	+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937	001	Dec 08, 1999	Jan	CPOT
	+		3309MG/10ML (330.9MG/ML)	N20937	002	Dec 08, 1999	Jan	NEWA
	+		4963.5MG/15ML (330.9MG/ML)	N20937	003	Dec 08, 1999	Jan	NEWA
	+		6618MG/20ML (330.9MG/ML)	N20937	004	Dec 08, 1999	Jan	NEWA
	+		16.545GM/50ML (330.9MG/ML)	N20975	001	Dec 08, 1999	Jan	CPOT

OPTIMARK IN PLASTIC CONTAINER

	+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976	001	Dec 08, 1999	Jan	CPOT
	+		3309MG/10ML (330.9MG/ML)	N20976	002	Dec 08, 1999	Jan	NEWA
	+		4963.5MG/15ML (330.9MG/ML)	N20976	003	Dec 08, 1999	Jan	NEWA
	+		6618MG/20ML (330.9MG/ML)	N20976	004	Dec 08, 1999	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
RAZADYNE ER

>D>	+	JANSSEN	EQ 8MG BASE	N21615	001	Dec 22, 2004	May	CMS2
>A>	+		EQ 8MG BASE	N21615	001	Apr 01, 2005	May	CMS2
>D>			EQ 16MG BASE	N21615	002	Dec 22, 2004	May	CMS2
>A>			EQ 16MG BASE	N21615	002	Apr 01, 2005	May	CMS2
>D>			EQ 24MG BASE	N21615	003	Dec 22, 2004	May	CMS2
>A>			EQ 24MG BASE	N21615	003	Apr 01, 2005	May	CMS2

GATIFLOXACIN

>D>		INJECTABLE; INJECTION							
>D>		TEQUIN							
>D>	+	BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	May	DISC	
>A>		@	400MG/40ML(10MG/ML)	N21062	004	Dec 17, 1999	May	DISC	
>D>		TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+	BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	May	DISC	
>A>		@	200MG/100ML(2MG/ML)	N21062	001	Dec 17, 1999	May	DISC	
>D>	+		400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	May	DISC	
>A>		@	400MG/200ML(2MG/ML)	N21062	002	Dec 17, 1999	May	DISC	
>D>		TABLET; ORAL							
>D>		TEQUIN							
>D>		BRISTOL MYERS SQUIBB	200MG	N21061	001	Dec 17, 1999	May	DISC	
>A>		@	200MG	N21061	001	Dec 17, 1999	May	DISC	
>D>	+		400MG	N21061	002	Dec 17, 1999	May	DISC	
>A>		@	400MG	N21061	002	Dec 17, 1999	May	DISC	

GLIMEPIRIDE

		TABLET; ORAL							
		GLIMEPIRIDE							
AB		COBALT	1MG	N77280	001	Feb 03, 2006	Jan	NEWA	
AB			2MG	N77280	002	Feb 03, 2006	Jan	NEWA	
AB			4MG	N77280	003	Feb 03, 2006	Jan	NEWA	
AB		GENPHARM	1MG	N77486	001	Feb 10, 2006	Jan	NEWA	
AB			2MG	N77486	002	Feb 10, 2006	Jan	NEWA	
AB			4MG	N77486	003	Feb 10, 2006	Jan	NEWA	

GLIPIZIDE

		TABLET; ORAL							
		GLIPIZIDE							
		@ ENDO PHARMS	5MG	N74378	001	Nov 28, 1994	Feb	DISC	
		@	10MG	N74378	002	Nov 28, 1994	Feb	DISC	
		TABLET, EXTENDED RELEASE; ORAL							
		GLIPIZIDE							
AB		WATSON LABS	2.5MG	N76467	003	Mar 27, 2006	Mar	NEWA	
		GLUCOTROL XL							
AB		PFIZER	2.5MG	N20329	003	Aug 10, 1999	Mar	CFTG	

GLYBURIDE

		TABLET; ORAL							
		DIABETA							
BX	+	SANOFI AVENTIS US	5MG	N17532	003	May 01, 1984	Feb	CRLD	

GUANFACINE HYDROCHLORIDE

		TABLET; ORAL							
		TENEX							
>A>	AB	DR REDDYS LABS INC	EQ 1MG BASE	N19032	001	Oct 27, 1986	May	CAHN	
>A>	AB +		EQ 2MG BASE	N19032	002	Nov 07, 1988	May	CAHN	
>A>		@	EQ 3MG BASE	N19032	003	Nov 07, 1988	May	CAHN	
>D>	AB	ESP PHARMA	EQ 1MG BASE	N19032	001	Oct 27, 1986	May	CAHN	
>D>	AB +		EQ 2MG BASE	N19032	002	Nov 07, 1988	May	CAHN	
>D>		@	EQ 3MG BASE	N19032	003	Nov 07, 1988	May	CAHN	

HALOBETASOL PROPIONATE

CREAM; TOPICAL
HALOBETASOL PROPIONATE

AB		PERRIGO ISRAEL	0.05%	N77123	001	Dec 16, 2004	Apr	CAHN

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE

AB		PERRIGO	0.05%	N76872	001	Dec 16, 2004	Mar	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO		SANDOZ	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Jan	CAHN
AO			EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Jan	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP		SANDOZ	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Jan	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
APRESOLINE

		@ NOVARTIS	10MG	N08303	004		Feb	DISC
		@	25MG	N08303	001		Feb	DISC
		@	50MG	N08303	002		Feb	DISC
		@	100MG	N08303	005		Feb	DISC

HYDRALAZINE HYDROCHLORIDE

>D>		@ ABC HOLDING	10MG	N88846	001	Feb 26, 1985	May	CAHN
>D>		@	25MG	N88847	001	Feb 26, 1985	May	CAHN
>D>		@	50MG	N88848	001	Feb 26, 1985	May	CAHN
>D>		@	100MG	N88849	001	Feb 26, 1985	May	CAHN
AA	+	PLIVA	10MG	N89097	001	Dec 18, 1985	Feb	CRLD
AA	+		25MG	N88467	001	May 01, 1984	Feb	CRLD
AA	+		50MG	N88468	001	May 01, 1984	Feb	CRLD
AA	+		100MG	N89098	001	Dec 18, 1985	Feb	CRLD
>A>		@ TG UNITED LABS	10MG	N88846	001	Feb 26, 1985	May	CAHN
>A>		@	25MG	N88847	001	Feb 26, 1985	May	CAHN
>A>		@	50MG	N88848	001	Feb 26, 1985	May	CAHN
>A>		@	100MG	N88849	001	Feb 26, 1985	May	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
CAM-AP-ES

>D>		@ ABC HOLDING	25MG;15MG;0.1MG	N84897	001		May	CAHN
>A>		@ TG UNITED LABS	25MG;15MG;0.1MG	N84897	001		May	CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

>D>		@ ABC HOLDING	25MG	N85683	001		May	CAHN
>D>		@	50MG	N83965	001		May	CAHN
>A>		@ TG UNITED LABS	25MG	N85683	001		May	CAHN
>A>		@	50MG	N83965	001		May	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO	12.5MG;10MG	N77606	001	Mar 14, 2006	Feb	NEWA
AB		12.5MG;20MG	N77606	002	Mar 14, 2006	Feb	NEWA
AB		25MG;20MG	N77606	003	Mar 14, 2006	Feb	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

	NOVARTIS	12.5MG;320MG	N20818	004	Apr 28, 2006	Apr	NEWA
		25MG;160MG	N20818	003	Jan 17, 2002	Apr	CRLD
+		25MG;320MG	N20818	005	Apr 28, 2006	Apr	NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N40666	001	Apr 06, 2006	Mar	NEWA

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	PHARMAFORCE	1%;EQ 3.5MG BASE;10,000 UNITS	N65219	001	May 01, 2006	Apr	NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

	BARR	EQ 100MG HCL	N88488	001	Jun 15, 1984	Mar	CTEC

VISTARIL

	@ PFIZER	EQ 100MG HCL	N11459	006		Mar	DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS
BONIVA

+	ROCHE	EQ 3MG BASE/3ML	N21858	001	Jan 06, 2006	Jan	NEWA

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS
NEOPROFEN

+	FARMACON IL	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903	001	Apr 13, 2006	Apr	NEWA

INDOMETHACIN

SUPPOSITORY; RECTAL
INDOMETHACIN

+	G AND W LABS	50MG	N73314	001	Aug 31, 1992	Apr	CTNA

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
APIDRA

+	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N21629	001	Apr 16, 2004	Mar	CMFD
+		300 UNITS/3ML (100 UNITS/ML)	N21629	002	Dec 20, 2005	Mar	CMFD

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

		EXUBERA							
		PFIZER	1MG/INH	N21868	001	Jan 27, 2006	Jan	NEWA	
	+		3MG/INH	N21868	002	Jan 27, 2006	Jan	NEWA	

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

>D>		ATROVENT							
>D>		+ BOEHRINGER INGELHEIM	0.018MG/INH	N19085	001	Dec 29, 1986	May	DISC	
>A>		@	0.018MG/INH	N19085	001	Dec 29, 1986	May	DISC	

SOLUTION; INHALATION

>D>		ATROVENT							
>D>	AN	+ BOEHRINGER INGELHEIM	0.02%	N20228	001	Sep 29, 1993	May	DISC	
>A>		@	0.02%	N20228	001	Sep 29, 1993	May	DISC	
		IPRATROPIUM BROMIDE							
>D>	AN	DEY	0.02%	N74755	001	Jan 10, 1997	May	CRLD	
>A>	AN	+	0.02%	N74755	001	Jan 10, 1997	May	CRLD	
>D>	AN	ROXANE	0.02%	N75867	001	Jul 22, 2002	May	DISC	
>A>		@	0.02%	N75867	001	Jul 22, 2002	May	DISC	

ISONIAZID

INJECTABLE; INJECTION

		ISONIAZID							
	AP	SANDOZ	100MG/ML	N40648	001	Jul 05, 2005	Jan	CAHN	

ISOSORBIDE MONONITRATE

TABLET; ORAL

		ISMO							
>A>	AB	DR REDDYS LABS INC	20MG	N19091	001	Dec 30, 1991	May	CAHN	
>D>	AB	ESP PHARMA	20MG	N19091	001	Dec 30, 1991	May	CAHN	

TABLET, EXTENDED RELEASE; ORAL

		ISOSORBIDE MONONITRATE							
	AB	WEST WARD	30MG	N76813	002	Mar 30, 2006	Mar	NEWA	

ISOTRETINOIN

CAPSULE; ORAL

		CLARAVIS							
>A>	AB	BARR	30MG	N76135	003	May 11, 2006	May	NEWA	
		SOTRET							
>D>		RANBAXY	30MG	N76503	001	Jun 20, 2003	May	CTEC	
>A>	AB		30MG	N76503	001	Jun 20, 2003	May	CTEC	

ISRADIPINE

CAPSULE; ORAL

>D>		DYNACIRC							
>D>	AB	+ RELIANT PHARMS	2.5MG	N19546	001	Dec 20, 1990	May	DISC	
>A>		@	2.5MG	N19546	001	Dec 20, 1990	May	DISC	
		ISRADIPINE							
	AB	ABRIKA PHARMS	5MG	N77317	002	Jan 05, 2006	Apr	CTEC	
	AB	AMIDE PHARM	2.5MG	N77169	001	Apr 24, 2006	Apr	NEWA	
	AB		5MG	N77169	002	Apr 24, 2006	Apr	NEWA	

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP		SANDOZ	15MG/ML	N76271	001	Oct 06, 2004	Jan	CAHN
AP			30MG/ML	N76271	002	Oct 06, 2004	Jan	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC
KETOTIFEN FUMARATE

AT		APOTEX	EQ 0.025% BASE	N77354	001	May 09, 2006	Apr	NEWA

ZADITOR

AT	+	NOVARTIS	EQ 0.025% BASE	N21066	001	Jul 02, 1999	Apr	CFTG

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
PREVACID NAPRAPAC 250 (COPACKAGED)

		TAP PHARM	15MG,N/A;N/A,250MG	N21507	002	Nov 14, 2003	Feb	CTNA

PREVACID NAPRAPAC 375 (COPACKAGED)

		TAP PHARM	15MG,N/A;N/A,375MG	N21507	003	Nov 14, 2003	Feb	CTNA

PREVACID NAPRAPAC 500 (COPACKAGED)

	+	TAP PHARM	15MG,N/A;N/A,500MG	N21507	004	Nov 14, 2003	Feb	CTNA

LEVETIRACETAM

TABLET; ORAL
KEPPRA

		UCB INC	750MG	N21035	003	Nov 30, 1999	Mar	CRLD
	+		1GM	N21035	004	Jan 06, 2006	Mar	NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETAXON

		@ ALCON	EQ 0.5% BASE	N21114	001	Feb 23, 2000	Feb	CAHN

>D>		LEVOCABASTINE HYDROCHLORIDE						
>D>		SUSPENSION/DROPS; OPHTHALMIC						
>D>		LIVOSTIN						
>D>	+	NOVARTIS	EQ 0.05% BASE	N20219	001	Nov 10, 1993	May	DISC
>A>		@	EQ 0.05% BASE	N20219	001	Nov 10, 1993	May	DISC

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
ANESTACON

AT	+	POLYMEDICA	2%	N80429	001		Jan	CDFR

LIDOCAINE; TETRACAINE

PATCH; TOPICAL
SYNERA

	+	ENDO PHARMS	70MG;70MG	N21623	001	Jun 23, 2005	Feb	CAHN

LISINOPRIL

TABLET; ORAL
LISINOPRIL

AB		AUROBINDO	2.5MG	N77622	001	Feb 22, 2006	Feb	NEWA
AB			5MG	N77622	002	Feb 22, 2006	Feb	NEWA

TABLET; ORAL
LISINOPRIL

AB	AUROBINDO	10MG	N77622	003	Feb 22, 2006	Feb	NEWA
AB		20MG	N77622	004	Feb 22, 2006	Feb	NEWA
AB		30MG	N77622	005	Feb 22, 2006	Feb	NEWA
AB		40MG	N77622	006	Feb 22, 2006	Feb	NEWA

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	MYLAN	0.5MG	N77657	001	Mar 16, 2006	Mar	NEWA
AB		1MG	N77657	002	Mar 16, 2006	Mar	NEWA
AB		2MG	N77657	003	Mar 16, 2006	Mar	NEWA
AB	VINTAGE PHARMS	0.5MG	N77754	001	May 10, 2006	Apr	NEWA
AB		1MG	N77754	002	May 10, 2006	Apr	NEWA
AB		2MG	N77754	003	May 10, 2006	Apr	NEWA

LOVASTATIN

TABLET; ORAL
LOVASTATIN

AB	MUTUAL PHARM	10MG	N77520	001	Apr 14, 2006	Apr	NEWA
AB		20MG	N77520	002	Apr 14, 2006	Apr	NEWA
AB		40MG	N77520	003	Apr 14, 2006	Apr	NEWA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
ADVICOR

+	KOS LIFE	20MG;750MG	N21249	002	Dec 17, 2001	Feb	CMFD

LUBIPROSTONE

CAPSULE; ORAL
AMITIZA

+	SUCAMPO PHARMS	24UGM	N21908	001	Jan 31, 2006	Jan	NEWA

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL
ZEGERID

	SANTARUS	700MG;20MG;600MG	N21850	001	Mar 24, 2006	Mar	NEWA
+		700MG;40MG;600MG	N21850	002	Mar 24, 2006	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

+	PHARMACIA AND UPJOHN	104MG/0.65ML	N21583	001	Dec 17, 2004	Jan	CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

AB	APOTEX	40MG/ML	N77404	001	Feb 16, 2006	Jan	NEWA

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

	@ ROXANE	600MG	N84332	001		Jan	DISC
	@ SANDOZ	200MG	N14547	002		Jan	DISC

TABLET; ORAL
MEPROBAMATE

		@	SANDOZ	400MG	N14547	001		Jan	DISC
		@		400MG	N80655	001		Jan	DISC
		@	SCHERER LABS	400MG	N83343	001		Jan	DISC
		@	TABLICAPS	400MG	N83494	001		Jan	DISC
	AA	+	WATSON LABS	200MG	N83304	001		Jan	CRLD
		@		200MG	N85720	001		Jan	DISC
		+		400MG	N83308	001		Jan	CRLD
		@		400MG	N85721	001		Jan	DISC

MILTOWN

		@	MEDPOINTE PHARM HLC	200MG	N09698	004		Jan	DISC
		@		400MG	N09698	002		Jan	DISC

TRANMEP

		@	SOLVAY	400MG	N16249	001		Jan	DISC

MESALAMINE

ENEMA; RECTAL
ROWASA

	AB	+	ALAVEN PHARM	4GM/60ML	N19618	001	Dec 24, 1987	Apr	CAHN

SUPPOSITORY; RECTAL
CANASA

>D>			AXCAN SCANDIPHARM	500MG	N21252	001	Jan 05, 2001	May	DISC
>A>		@		500MG	N21252	001	Jan 05, 2001	May	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

>A>	AB		INTERPHARM	500MG	N77880	001	Jun 05, 2006	May	NEWA
>A>	AB			850MG	N77880	002	Jun 05, 2006	May	NEWA
>A>	AB			1GM	N77880	003	Jun 05, 2006	May	NEWA

TABLET, EXTENDED RELEASE; ORAL
GLUMETZA

	BX		DEPOMED INC	500MG	N21748	001	Jun 03, 2005	Jan	CAHN
	BX			1GM	N21748	002	Jun 03, 2005	Jan	CAHN

METFORMIN HYDROCHLORIDE

	AB		SUN PHARM INDS (IN)	500MG	N77336	001	Feb 09, 2006	Jan	NEWA
	AB			750MG	N77336	002	Feb 09, 2006	Jan	NEWA

METHIMAZOLE

TABLET; ORAL
METHIMAZOLE

>D>			CEDAR PHARMS	20MG	N40547	004	Feb 18, 2005	May	CRLD
>A>		+		20MG	N40547	004	Feb 18, 2005	May	CRLD
>D>	AB		JONES PHARMA	5MG	N40320	001	Mar 31, 2000	May	CTNA
>D>	AB			10MG	N40320	002	Mar 31, 2000	May	CTNA

TAPAZOLE

>A>	AB		JONES PHARMA	5MG	N40320	001	Mar 31, 2000	May	CTNA
>A>	AB			10MG	N40320	002	Mar 31, 2000	May	CTNA

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE PRESERVATIVE FREE

		+	BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12, 2005	Apr	CAIN
		+	MAYNE PHARMA USA	EQ 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	CPOT

INJECTABLE; INJECTION
METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
	+		EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CTEC
	+		EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CTEC
	+		EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CTEC

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL
DAYTRANA

	+	SHIRE	10MG/9HR (1.1MG/HR)	N21514	001	Apr 06, 2006	Apr	NEWA
	+		15MG/9HR (1.6MG/HR)	N21514	002	Apr 06, 2006	Apr	NEWA
	+		20MG/9HR (2.2MG/HR)	N21514	003	Apr 06, 2006	Apr	NEWA
	+		30MG/9HR (3.3MG/HR)	N21514	004	Apr 06, 2006	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX		UCB INC	40MG	N21259	004	Feb 19, 2006	Feb	NEWA
			50MG	N21259	005	Feb 19, 2006	Feb	NEWA
	+		60MG	N21259	006	Feb 19, 2006	Feb	NEWA

RITALIN LA

BX	+	NOVARTIS	40MG	N21284	003	Jun 05, 2002	Feb	CTEC

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HYDROCHLORIDE

AB		MUTUAL PHARM	EQ 5MG BASE	N71536	002	Jan 16, 1997	Apr	CMFD
AB			EQ 10MG BASE	N71536	001	Apr 28, 1993	Apr	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL
REGLAN ODT

>D>		SCHWARZ PHARMA	EQ 5MG BASE	N21793	001	Jun 10, 2005	May	DISC
>A>		@	EQ 5MG BASE	N21793	001	Jun 10, 2005	May	DISC
>D>	+		EQ 10MG BASE	N21793	002	Jun 10, 2005	May	DISC
>A>		@	EQ 10MG BASE	N21793	002	Jun 10, 2005	May	DISC

METRONIDAZOLE

GEL; TOPICAL
METROGEL

>D>	+	GALDERMA LABS LP	0.75%	N19737	001	Nov 22, 1988	May	CFTG
>A> AB	+		0.75%	N19737	001	Nov 22, 1988	May	CFTG

>A> METRONIDAZOLE

>A> AB		ALTANA	0.75%	N77018	001	Jun 06, 2006	May	NEWA

LOTION; TOPICAL
METROLOTION

>D>	+	GALDERMA LABS LP	0.75%	N20901	001	Nov 24, 1998	May	CFTG
>A> AB	+		0.75%	N20901	001	Nov 24, 1998	May	CFTG

METRONIDAZOLE

>A> AB		ALTANA	0.75%	N77197	001	May 24, 2006	May	NEWA

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL
VUSION

	+	BARRIER	0.25%;81.35%;15%	N21026	001	Feb 16, 2006	Feb	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP	+	HOSPIRA	EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

AB		TRIAX PHARMS	EQ 50MG BASE	N50649	001	May 31, 1990	Feb	CAHN
	@		EQ 75MG BASE	N50649	003	Feb 12, 2001	Feb	CAHN
AB	+		EQ 100MG BASE	N50649	002	May 31, 1990	Feb	CAHN
>A>		TABLET, EXTENDED RELEASE; ORAL						
>A>		SOLODYN						
>A>		MEDICIS	EQ 45MG BASE	N50808	001	May 08, 2006	May	NEWA
>A>			EQ 90MG BASE	N50808	002	May 08, 2006	May	NEWA
>A>	+		EQ 135MG BASE	N50808	003	May 08, 2006	May	NEWA

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	45MG	N77376	004	Feb 28, 2006	Feb	NEWA
AB		BARR	45MG	N76307	003	Feb 28, 2006	Feb	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
MITOXANTRONE

AP		AM PHARM	EQ 20MG BASE/10ML (2MG/ML)	N77496	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N77496	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N77496	003	Apr 11, 2006	Mar	NEWA
AP		BEDFORD	EQ 20MG BASE/10ML (2MG/ML)	N76611	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N76611	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N76611	003	Apr 11, 2006	Mar	NEWA
AP		MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N76871	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N76871	003	Apr 11, 2006	Mar	NEWA
AP		SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N77356	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N77356	003	Apr 11, 2006	Mar	NEWA

NOVANTRONE

AP	+	SERONO INC	EQ 20MG BASE/10ML(2MG/ML)	N19297	001	Dec 23, 1987	Mar	CFTG
AP	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297	002	Dec 23, 1987	Mar	CFTG
AP	+		EQ 30MG BASE/15ML (2MG/ML)	N19297	003	Dec 23, 1987	Mar	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL
MOMETASONE FUROATE

>A>	AB		G AND W LABS	0.1%	N77447	001	May 22, 2006	May	NEWA

LOTION; TOPICAL
MOMETASONE FUROATE

AB		PERRIGO	0.1%	N77180	001	Apr 06, 2005	Mar	CAHN
AB		TARO	0.1%	N76788	001	Mar 15, 2006	Feb	NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE

		HOSPIRA	5MG/ML	N19916	002	Mar 30, 2006	Mar	NEWA

NABILONE

CAPSULE; ORAL
CESAMET

>D>		@ VALEANT	1MG	N18677	001	Dec 26, 1985	May	CMFD
>A>	+		1MG	N18677	001	Dec 26, 1985	May	CMFD

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		PAR PHARM	500MG	N76009	001	Jan 24, 2003	Apr	CAHN
AB			750MG	N76009	002	Jan 24, 2003	Apr	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	+	SANDOZ	EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Apr	CRLD
AP	+		EQ 1GM BASE/VIAL	N62732	001	Dec 23, 1986	Apr	CRLD
AP	+		EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Apr	CRLD
AP	+		EQ 2GM BASE/VIAL	N62732	002	Dec 23, 1986	Apr	CRLD
AP	+		EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Apr	CRLD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
VIVITROL

	+	ALKERMES	380MG/VIAL	N21897	001	Apr 13, 2006	Apr	NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN AND POLYMYXIN B SULFATE

AT		X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106	001	Jan 31, 2006	Jan	NEWA
AT			EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108	001	Jan 31, 2006	Jan	NEWA

NEOSPORIN G.U. IRRIGANT

AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001		Jan	CTEC
AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707	002		Jan	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HYDROCHLORIDE

AB		BARR	20MG	N74439	001	Dec 10, 1996	Apr	CAHN
AB			30MG	N74439	002	Dec 10, 1996	Apr	CAHN

INJECTABLE; INJECTION
CARDENE

	+	PDL BIOPHARMA INC	2.5MG/ML	N19734	001	Jan 30, 1992	Jan	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
AFEDITAB CR

AB1	WATSON LABS	30MG	N75128	001	Mar 10, 2000	Jan	CAHN
AB1		60MG	N75659	001	Oct 26, 2001	Jan	CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

>A> AP	METRICS PHARM	EQ 1MG BASE/ML	N40522	001	Sep 30, 2004	May	CAHN
>D> AP	PHARMAFORCE	EQ 1MG BASE/ML	N40522	001	Sep 30, 2004	May	CAHN

NYSTATIN

CREAM; TOPICAL
NYSTATIN

>D> AT	TARO	100,000 UNITS/GM	N62457	001	Jul 28, 1983	May	DISC
>A>	@	100,000 UNITS/GM	N62457	001	Jul 28, 1983	May	DISC
>A> AT	VINTAGE	100,000 UNITS/GM	N65315	001	May 31, 2006	May	NEWA

SUSPENSION; ORAL
NYSTATIN

>D>	@ TARO	100,000 UNITS/ML	N62876	001	Feb 29, 1988	May	CMFD
>A> AA		100,000 UNITS/ML	N62876	001	Feb 29, 1988	May	CMFD

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

AP	AM PHARM	EQ 0.2MG BASE/ML	N77450	001	Feb 10, 2006	Jan	NEWA
AP		EQ 1MG BASE/ML	N77450	002	Feb 10, 2006	Jan	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	AM PHARM	EQ 0.05MG BASE/ML	N77457	001	Feb 10, 2006	Jan	NEWA
AP		EQ 0.1MG BASE/ML	N77457	002	Feb 10, 2006	Jan	NEWA
AP		EQ 0.5MG BASE/ML	N77457	003	Feb 10, 2006	Jan	NEWA

OFLOXACIN

TABLET; ORAL
OFLOXACIN

AB	DR REDDYS LABS LTD	200MG	N77098	001	Feb 10, 2006	Jan	NEWA
AB		300MG	N77098	002	Feb 10, 2006	Jan	NEWA
AB		400MG	N77098	003	Feb 10, 2006	Jan	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL
ZEGERID

	SANTARUS	20MG;1.1GM	N21849	001	Feb 27, 2006	Feb	NEWA
+		40MG;1.1GM	N21849	002	Feb 27, 2006	Feb	NEWA

FOR SUSPENSION; ORAL
ZEGERID

	SANTARUS	20MG/PACKET;1.68GM/PACKET	N21636	001	Jun 15, 2004	Feb	CAIN
+		40MG/PACKET;1.68GM/PACKET	N21706	001	Dec 21, 2004	Feb	CAIN

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
ORPHENADRINE CITRATE

>A> AP	AKORN	30MG/ML	N40484	001	May 24, 2006	May	NEWA

OXYMETHOLONE

TABLET; ORAL
ANADROL-50

	+	ALAVEN PHARM	50MG	N16848	001		Apr	CAHN

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)
ABRAXANE

	+	ABRAXIS BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Apr	CAHN

PAROXETINE MESYLATE

TABLET; ORAL
PEXEVA

		JDS PHARMS	EQ 10MG BASE	N21299	001	Jul 03, 2003	Apr	CAHN
			EQ 20MG BASE	N21299	002	Jul 03, 2003	Apr	CAHN
			EQ 30MG BASE	N21299	003	Jul 03, 2003	Apr	CAHN
	+		EQ 40MG BASE	N21299	004	Jul 03, 2003	Apr	CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL
MACUGEN

>D>	+	EYETECH PHARMS	EQ 0.3MG ACID/0.09ML	N21756	001	Dec 17, 2004	May	CAHN
>A>	+	OSI EYETECH	EQ 0.3MG ACID/0.09ML	N21756	001	Dec 17, 2004	May	CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL
PENICILLIN V POTASSIUM

AA		AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529	001		Jan	CAHN
AA			EQ 250MG BASE/5ML	N61529	002		Jan	CAHN

TABLET; ORAL
PENICILLIN V POTASSIUM

		@ AM ANTIBIOTICS	EQ 250MG BASE	N61528	001		Jan	CAHN
		@	EQ 500MG BASE	N61528	002		Jan	CAHN

PERGOLIDE MESYLATE

TABLET; ORAL
PERGOLIDE MESYLATE

AB		PAR PHARM	EQ 0.05MG BASE	N76061	001	Nov 27, 2002	Apr	CAHN
AB			EQ 0.25MG BASE	N76061	002	Nov 27, 2002	Apr	CAHN
AB			EQ 1MG BASE	N76061	003	Nov 27, 2002	Apr	CAHN

PERMAX

AB		VALEANT	EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Jan	CRLD
AB	+		EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Jan	CRLD

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
CAM-METRAZINE

>D>		@ ABC HOLDING	35MG	N83922	001		May	CAHN
>D>		@	35MG	N85318	001		May	CAHN
>D>		@	35MG	N85320	001		May	CAHN
>D>		@	35MG	N85321	001		May	CAHN
>A>		@ TG UNITED LABS	35MG	N83922	001		May	CAHN
>A>		@	35MG	N85318	001		May	CAHN
>A>		@	35MG	N85320	001		May	CAHN

TABLET; ORAL
CAM-METRAZINE
>A> @ TG UNITED LABS 35MG N85321 001 May CAHN
PHENDIMETRAZINE TARTRATE
>D> @ ABC HOLDING 35MG N85761 001 May CAHN
>D> @ 35MG N85941 001 Jun 27, 1983 May CAHN
>A> @ TG UNITED LABS 35MG N85761 001 May CAHN
>A> @ 35MG N85941 001 Jun 27, 1983 May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE
>D> @ ABC HOLDING 18.75MG N88576 001 May 23, 1984 May CAHN
>D> @ 30MG N85417 001 May CAHN
>D> @ 30MG N86732 002 May CAHN
>D> @ 30MG N87215 001 May CAHN
>D> @ 37.5MG N87915 001 Dec 22, 1983 May CAHN
>D> @ 37.5MG N87918 001 Dec 22, 1983 May CAHN
>D> @ 37.5MG N87930 001 Oct 14, 1983 May CAHN
>D> @ 37.5MG N88610 001 Jun 04, 1984 May CAHN
>D> @ 37.5MG N88611 001 Jun 04, 1984 May CAHN
>D> @ 37.5MG N88625 001 Aug 23, 1984 May CAHN
>A> @ TG UNITED LABS 18.75MG N88576 001 May 23, 1984 May CAHN
>A> @ 30MG N85417 001 May CAHN
>A> @ 30MG N86732 002 May CAHN
>A> @ 30MG N87215 001 May CAHN
>A> @ 37.5MG N87915 001 Dec 22, 1983 May CAHN
>A> @ 37.5MG N87918 001 Dec 22, 1983 May CAHN
>A> @ 37.5MG N87930 001 Oct 14, 1983 May CAHN
>A> @ 37.5MG N88610 001 Jun 04, 1984 May CAHN
>A> @ 37.5MG N88611 001 Jun 04, 1984 May CAHN
>A> @ 37.5MG N88625 001 Aug 23, 1984 May CAHN

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE
>D> @ ABC HOLDING 8MG N83923 001 May CAHN
>D> @ 8MG N85319 001 May CAHN
>D> @ 37.5MG N87805 001 Dec 06, 1982 May CAHN
>D> @ 37.5MG N88596 001 Apr 04, 1984 May CAHN
>A> @ TG UNITED LABS 8MG N83923 001 May CAHN
>A> @ 8MG N85319 001 May CAHN
>A> @ 37.5MG N87805 001 Dec 06, 1982 May CAHN
>A> @ 37.5MG N88596 001 Apr 04, 1984 May CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH VC PLAIN
\+ ALPHARMA US PHARMS 5MG/5ML;6.25MG/5ML N88761 001 Nov 08, 1984 Jan CTEC
PROMETHAZINE VC PLAIN
@ MORTON GROVE 5MG/5ML;6.25MG/5ML N88897 001 Jan 04, 1985 Jan DISC

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
@ MERCK 1MG/0.5ML N12223 002 Feb DISC
@ 10MG/ML N12223 001 Feb DISC

INJECTABLE; INJECTION
VITAMIN K1

BP	+	HOSPIRA	1MG/0.5ML	N87954	001	Jul 25, 1983	Feb	CRLD
	+		10MG/ML	N87955	001	Jul 25, 1983	Feb	CRLD

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL
PILOCARPINE HYDROCHLORIDE

AB		IMPAX LABS	5MG	N77248	001	Mar 31, 2006	Mar	NEWA
AB			7.5MG	N77248	002	Mar 31, 2006	Mar	NEWA

SALAGEN

AB	+	MGI PHARMA INC	7.5MG	N20237	002	Apr 18, 2003	Mar	CFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

>A>	AA	COASTAL PHARMS	17GM/SCOOPFUL	N77893	001	May 26, 2006	May	NEWA
>A>	AA	KALI LABS	17GM/SCOOPFUL	N77736	001	May 26, 2006	May	NEWA
	AA	TEVA PHARMS	17GM/SCOOPFUL	N77445	001	May 04, 2006	Apr	NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KLOR-CON

AB		UPSHER SMITH	8MEQ	N19123	001	Apr 17, 1986	Jan	CRLD

POTASSIUM CHLORIDE

AB	+	COPLEY PHARM	8MEQ	N70618	001	Sep 09, 1987	Jan	CRLD

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
>A> POTASSIUM CITRATE

>A>	AB	COREPHARMA	5MEQ	N77440	001	Jun 09, 2006	May	NEWA
>A>	AB		10MEQ	N77440	002	Jun 09, 2006	May	NEWA

UROCIT-K

>D>		MISSION PHARMA	5MEQ	N19071	001	Aug 30, 1985	May	CFTG
>A>	AB		5MEQ	N19071	001	Aug 30, 1985	May	CFTG
>D>	+		10MEQ	N19071	002	Aug 31, 1992	May	CFTG
>A>	AB	+	10MEQ	N19071	002	Aug 31, 1992	May	CFTG

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL

AB		BRISTOL MYERS SQUIBB	10MG	N19898	002	Oct 31, 1991	Apr	CFTG
AB			20MG	N19898	003	Oct 31, 1991	Apr	CFTG
AB			40MG	N19898	004	Mar 22, 1993	Apr	CFTG

PRAVASTATIN SODIUM

AB		TEVA	10MG	N76056	001	Apr 24, 2006	Apr	NEWA
AB			20MG	N76056	002	Apr 24, 2006	Apr	NEWA
AB			40MG	N76056	003	Apr 24, 2006	Apr	NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HYDROCHLORIDE

	@	CLONMEL HLTHCARE	EQ 1MG BASE	N72705	001	May 16, 1989	Jan	DISC
	@		EQ 5MG BASE	N72707	001	May 16, 1989	Jan	DISC

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

		@ STERIS	25MG/ML	N83398	001		Mar	DISC
		@	50MG/ML	N83764	001		Mar	DISC

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

>D>	AB	FALCON PHARMS	1%	N17469	001		May	CTNA

OMNIPRED

>A>	AB	ALCON	1%	N17469	001		May	CTNA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPAZINE

>D>		GLAXOSMITHKLINE	2.5MG	N11127	003		May	DISC
>A>		@	2.5MG	N11127	003		May	DISC
>D>			5MG	N11127	001		May	DISC
>A>		@	5MG	N11127	001		May	DISC

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL
COMPAZINE

>D>		GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N11188	001		May	DISC
>A>		@	EQ 5MG BASE/5ML	N11188	001		May	DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
COMPAZINE

>D>	+	GLAXOSMITHKLINE	EQ 10MG BASE	N21019	001	Oct 06, 1999	May	DISC
>A>		@	EQ 10MG BASE	N21019	001	Oct 06, 1999	May	DISC

PROGESTERONE

GEL; VAGINAL
CRINONE

>A>		COLUMBIA LABS	4%	N20701	001	Jul 31, 1997	May	CAHN
>A>	+		8%	N20701	002	Jul 31, 1997	May	CAHN
>D>		COLUMBIA RES LABS	4%	N20701	001	Jul 31, 1997	May	CAHN
>D>	+		8%	N20701	002	Jul 31, 1997	May	CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PHENERGAN

		@ WYETH PHARMS INC	12.5MG	N10926	002		Mar	DISC
		@	25MG	N10926	001		Mar	DISC

PROMETHAZINE HYDROCHLORIDE

AB	+	G AND W LABS	25MG	N40428	001	Feb 05, 2002	Mar	CRLD

PROMETHEGAN

	+	G AND W LABS	50MG	N87165	001	Aug 14, 1987	Jan	CRLD

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

AA		VINTAGE	6.25MG/5ML	N40643	001	Apr 26, 2006	Apr	NEWA

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB	HOSPIRA	10MG/ML	N77908	001	Mar 17, 2006	Mar	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HYDROCHLORIDE

AA	PAR PHARM	65MG	N80269	001		Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	SANDOZ	1MG/ML	N76400	001	Feb 26, 2003	Jan	CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
REGONOL

AP	SANDOZ	5MG/ML	N17398	001		Jan	CAHN

QUAZEPAM

TABLET; ORAL
DORAL

>D>	@ MEDPOINTE PHARM HLC	7.5MG	N18708	003	Feb 26, 1987	May	CAHN
>D>	+	15MG	N18708	001	Dec 27, 1985	May	CAHN
>A>	@ QUESTCOR PHARMS	7.5MG	N18708	003	Feb 26, 1987	May	CAHN
>A>	+	15MG	N18708	001	Dec 27, 1985	May	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

AB	TORPHARM	EQ 5MG BASE	N76240	001	Jan 26, 2006	Jan	NEWA
AB		EQ 10MG BASE	N76240	002	Jan 26, 2006	Jan	NEWA
AB		EQ 20MG BASE	N76240	003	Jan 26, 2006	Jan	NEWA
AB		EQ 40MG BASE	N76240	004	Jan 26, 2006	Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

BX	+ MUTUAL PHARM	324MG	N89338	001	Feb 11, 1987	Jan	CTEC
BX	WATSON LABS	324MG	N87810	001	Sep 29, 1982	Jan	CMFD

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

	@ CLONMEL HLTHCARE	200MG	N87011	001		Jan	DISC
	@ LANNETT	200MG	N83743	001		Jan	DISC
	@ MUTUAL PHARM	100MG	N81029	001	Apr 14, 1989	Jan	DISC
	@ PHARM FORM	200MG	N83808	001		Jan	DISC
	@ SANDOZ	200MG	N84631	001		Jan	DISC
	@	200MG	N84914	001		Jan	DISC
AB		200MG	N88072	002		Jan	NEWA
	@	300MG	N89839	001	Sep 29, 1988	Jan	DISC
	@ WATSON LABS	200MG	N83288	001		Jan	DISC

TABLET; ORAL
QUINIDINE SULFATE

		@ WATSON LABS	200MG	N85140	002		Jan	DISC

RANITIDINE

INJECTABLE; INJECTION
RANITIDINE

	AP	BEDFORD	EQ 25MG BASE/ML	N77458	001	Feb 16, 2006	Feb	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL
RANEXA

	+	CV THERAP	500MG	N21526	002	Jan 27, 2006	Jan	NEWA

RASAGILINE MESYLATE

TABLET; ORAL
AZILECT

>A>		TEVA	EQ 0.5MG BASE	N21641	001	May 16, 2006	May	NEWA
>A>	+		EQ 1MG BASE	N21641	002	May 16, 2006	May	NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

		JANSSEN PHARMA	3MG	N21444	004	Dec 23, 2004	Mar	CMFD
			4MG	N21444	005	Dec 23, 2004	Mar	CMFD

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS
SECREFLO

>A>	+	CHIRHOCLIN	16UGM/VIAL	N21136	001	Apr 04, 2002	May	CTNA

SECREMAX

>D>	+	CHIRHOCLIN	16UGM/VIAL	N21136	001	Apr 04, 2002	May	CTNA

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

		SOMERSET	6MG/24HR	N21336	001	Feb 27, 2006	Mar	CAIN
			9MG/24HR	N21336	002	Feb 27, 2006	Mar	CAIN
	+		12MG/24HR	N21336	003	Feb 27, 2006	Mar	CAIN

SELEGILINE HYDROCHLORIDE

FILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

		SOMERSET	6MG/24HR	N21336	001	Feb 27, 2006	Feb	NEWA
			9MG/24HR	N21336	002	Feb 27, 2006	Feb	NEWA
	+		12MG/24HR	N21336	003	Feb 27, 2006	Feb	NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	B BRAUN	900MG/100ML	N17464	001		May	CRLD
>A>	AP	+	900MG/100ML	N17464	001		May	CRLD
>D>	AP		900MG/100ML	N19635	002	Mar 09, 1988	May	CRLD
>A>	AP	+	900MG/100ML	N19635	002	Mar 09, 1988	May	CRLD
>D>	AP	BAXTER HLTHCARE	900MG/100ML	N16677	001		May	CRLD

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	AP	+	BAXTER HLTHCARE	900MG/100ML	N16677	001			May	CRLD
>D>	AP			900MG/100ML	N20178	001	Dec 07, 1992		May	CRLD
>A>	AP	+		900MG/100ML	N20178	001	Dec 07, 1992		May	CRLD
>D>	AP		HOSPIRA	900MG/100ML	N16366	001			May	CRLD
>A>	AP	+		900MG/100ML	N16366	001			May	CRLD
>D>	AP			900MG/100ML	N19465	001	Jul 15, 1985		May	CRLD
>A>	AP	+		900MG/100ML	N19465	001	Jul 15, 1985		May	CRLD
>D>	AP			900MG/100ML	N19480	001	Sep 17, 1985		May	CRLD
>A>	AP	+		900MG/100ML	N19480	001	Sep 17, 1985		May	CRLD

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
OSMOPREP

		+	SALIX PHARMS	0.398GM;1.102GM	N21892	001	Mar 16, 2006		Mar	NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
GENOTROPIN

>D>		+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280	006	Aug 24, 1995		May	CTEC
>A>	BX	+		5.8MG/VIAL	N20280	006	Aug 24, 1995		May	CTEC

GENOTROPIN PRESERVATIVE FREE

>D>			PHARMACIA AND UPJOHN	1.5MG/VIAL	N20280	004	Aug 24, 1995		May	CTEC
>A>	BX			1.5MG/VIAL	N20280	004	Aug 24, 1995		May	CTEC

OMNITROPE

>A>	BX		SANDOZ	1.5MG/VIAL	N21426	002	May 30, 2006		May	NEWA
>A>	BX			5.8MG/VIAL	N21426	001	May 30, 2006		May	NEWA

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

	AB		PUREPAC PHARM	25MG	N40353	003	Mar 15, 2006		Feb	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE

	AP	+	SANDOZ	20MG/ML	N08453	002			Jan	CAHN
		@		50MG/ML	N08453	003			Jan	CAHN
		@		500MG/VIAL	N08453	001			Jan	CAHN
		@		1GM/VIAL	N08453	004			Jan	CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

	AT		ALCON	30%	N89068	001	May 05, 1987		Apr	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
BACTRIM PEDIATRIC

	AB		MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560	002			Apr	CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
IMITREX
+ GLAXOSMITHKLINE EQ 6MG BASE/0.5ML (12MG/ML) N20080 001 Dec 28, 1992 Feb CDFR
IMITREX STATDOSE
+ GLAXOSMITHKLINE EQ 4MG BASE/0.5ML (8MG/ML) N20080 002 Feb 01, 2006 Feb NEWA
+ EQ 6MG BASE/0.5ML (12MG/ML) N20080 003 Dec 23, 1996 Feb NEWA

SUNITINIB MALATE

CAPSULE; ORAL
SUTENT
PFIZER 12.5MG N21938 001 Jan 26, 2006 Jan NEWA
25MG N21938 002 Jan 26, 2006 Jan NEWA
+ 50MG N21938 003 Jan 26, 2006 Jan NEWA

>D> TECHNETIUM TC-99M APCITIDE

>D> INJECTABLE; INJECTION
>D> ACUTECT
>D> CIS BIO INTL SA N/A N20887 001 Sep 14, 1998 May DISC
>A> @ N/A N20887 001 Sep 14, 1998 May DISC
N/A N20887 001 Sep 14, 1998 Apr CAHN

>D> TECHNETIUM TC-99M DEPREOTIDE

>D> INJECTABLE; INJECTION
>D> NEO TECT KIT
>D> + CIS BIO INTL SA N/A N21012 001 Aug 03, 1999 May DISC
>A> @ N/A N21012 001 Aug 03, 1999 May DISC
+ N/A N21012 001 Aug 03, 1999 Apr CAHN

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
>D> MYOVIEW 30ML
>D> + GE HEALTHCARE N/A N20372 002 Jul 07, 2005 May DISC
>A> @ N/A N20372 002 Jul 07, 2005 May DISC

TERCONAZOLE

SUPPOSITORY; VAGINAL
TERAZOL 3
AB + ORTHO MCNEIL PHARM 80MG N19641 001 May 24, 1988 Mar CFTG
TERCONAZOLE
AB PERRIGO NEW YORK 80MG N77149 001 Mar 17, 2006 Mar NEWA

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL
AB + UNIMED PHARMS 1% N21015 001 Feb 28, 2000 Jan CTEC
TESTOSTERONE
AB WATSON LABS 1% N76737 001 Jan 27, 2006 Jan NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL
@ INDEVUS PHARMS 200MG/ML N09165 001 Jan CAHN
AO + 200MG/ML N09165 003 Jan CAHN

INJECTABLE; INJECTION
TESTOSTERONE ETHANATE

>A>	AO	PADDOCK	200MG/ML	N40575	001	Jun 14, 2006	May	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

>A>		@ RADIUS PHARMS	250MG	N50278	003		May	CAHN
>A>		@	500MG	N50278	001		May	CAHN
>D>		@ SCIREG INTL INC	250MG	N50278	003		May	CAHN
		@	250MG	N50278	003		Apr	CAHN
>D>		@	500MG	N50278	001		May	CAHN
		@	500MG	N50278	001		Apr	CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

	AP	TRACE RADIOCHEMICALS	1mCi/ML	N75569	001	Nov 21, 2001	Feb	CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

	AB	NOSTRUM	400MG	N40595	001	Apr 21, 2006	Apr	NEWA
	AB		600MG	N40560	002	Apr 21, 2006	Apr	NEWA

UNIPHYL

	AB +	PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	Apr	CTEC
	AB +		600MG	N40086	001	Apr 15, 1996	Apr	CTEC

>D> TICARCILLIN DISODIUM

>D> INJECTABLE; INJECTION
>D> TICAR

>D>	+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50497	001		May	DISC
>A>		@	EQ 1GM BASE/VIAL	N50497	001		May	DISC
>D>	+		EQ 3GM BASE/VIAL	N50497	002		May	DISC
>A>		@	EQ 3GM BASE/VIAL	N50497	002		May	DISC
>D>	+		EQ 20GM BASE/VIAL	N50497	004		May	DISC
>A>		@	EQ 20GM BASE/VIAL	N50497	004		May	DISC
>D>	+		EQ 30GM BASE/VIAL	N50497	005	Apr 04, 1984	May	DISC
>A>		@	EQ 30GM BASE/VIAL	N50497	005	Apr 04, 1984	May	DISC

TINIDAZOLE

TABLET; ORAL
TINDAMAX

		MISSION PHARMA	250MG	N21618	001	May 17, 2004	Jan	CAHN
	+		500MG	N21618	002	May 17, 2004	Jan	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

		@ IVAX PHARMS	50MG	N75963	001	Jul 03, 2002	Jan	DISC

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

>A>	AT	VINTAGE	0.025%	N40671	001	Jun 09, 2006	May	NEWA

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

>A>	AT	VINTAGE	0.1%	N40671	002	Jun 09, 2006	May	NEWA

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT

		@ SANDOZ	25MG/ML	N11685	003		Jan	CAHN
		@	40MG/ML	N12802	001		Jan	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION
ARISTOSPAN

	+	SANDOZ	5MG/ML	N16466	001		Jan	CAHN
	+		20MG/ML	N16466	002		Jan	CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMETHIAZIDE

>D>		@ ABC HOLDING	4MG	N85568	001		May	CAHN
>A>		@ TG UNITED LABS	4MG	N85568	001		May	CAHN

TRIFLUOPERAZINE HYDROCHLORIDE

>D> INJECTABLE; INJECTION
>D> STELAZINE

>D>	+	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552	005		May	DISC
>A>		@	EQ 2MG BASE/ML	N11552	005		May	DISC

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
PBZ

		@ NOVARTIS	50MG	N05914	002		Jan	DISC

TROLEANDOMYCIN

CAPSULE; ORAL
TAO

		@ PFIZER	EQ 250MG BASE	N50336	002		Mar	DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA

	+	R TECH UENO LTD	0.15%	N21214	001	Aug 03, 2000	Feb	CAHN

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE

		@ IMARX THERAP	5,000 IU/VIAL	N21846	003		Apr	CAHN
		@	9,000 IU/VIAL	N21846	002		Apr	CAHN
	+		250,000 IU/VIAL	N21846	001		Apr	CAHN

>A> VARENICLINE TARTRATE

>A> TABLET; ORAL
>A> CHANTIX

>A>		PFIZER	EQ 0.5MG BASE	N21928	001	May 10, 2006	May	NEWA
>A>	+		EQ 1MG BASE	N21928	002	May 10, 2006	May	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

	AP	+	BEDFORD	20MG/VIAL	N75549	002	Jun 13, 2000	Jan	CRLD

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

>A>	AB		ZYDUS PHARMS USA	1MG	N40663	001	May 30, 2006	May	NEWA
>A>	AB			2MG	N40663	002	May 30, 2006	May	NEWA
>A>	AB			2.5MG	N40663	003	May 30, 2006	May	NEWA
>A>	AB			3MG	N40663	004	May 30, 2006	May	NEWA
>A>	AB			4MG	N40663	005	May 30, 2006	May	NEWA
>A>	AB			5MG	N40663	006	May 30, 2006	May	NEWA
>A>	AB			6MG	N40663	007	May 30, 2006	May	NEWA
>A>	AB			7.5MG	N40663	008	May 30, 2006	May	NEWA
>A>	AB			10MG	N40663	009	May 30, 2006	May	NEWA

ZIDOVUDINE

CAPSULE; ORAL
RETROVIR

	AB	+	GLAXOSMITHKLINE	100MG	N19655	001	Mar 19, 1987	Mar	CFTG

ZIDOVUDINE

	AB		AUROBINDO PHARMA LTD	100MG	N78128	001	Mar 27, 2006	Mar	NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL
GEODON

		+	PFIZER INC	EQ 10MG BASE/ML	N21483	001	Mar 29, 2006	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL
ZONISAMIDE

	AB		GLENMARK PHARMS	25MG	N77651	001	Jan 30, 2006	Jan	NEWA
	AB			50MG	N77651	002	Jan 30, 2006	Jan	NEWA
	AB			100MG	N77651	003	Jan 30, 2006	Jan	NEWA
>A>	AB		INVAGEN PHARMS	25MG	N77869	001	May 31, 2006	May	NEWA
>A>	AB			50MG	N77869	002	May 31, 2006	May	NEWA
>A>	AB			100MG	N77869	003	May 31, 2006	May	NEWA
	AB		SUN PHARM INDS (IN)	25MG	N77634	001	Mar 17, 2006	Mar	NEWA
	AB			50MG	N77634	002	Mar 17, 2006	Mar	NEWA
	AB			100MG	N77634	003	Mar 17, 2006	Mar	NEWA
	AB		WATSON LABS	25MG	N77650	001	Apr 20, 2006	Apr	NEWA
	AB			50MG	N77650	002	Apr 20, 2006	Apr	NEWA
	AB			100MG	N77650	003	Apr 20, 2006	Apr	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2006

NO MAY 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 2006 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM						
021652 001	5034394	Dec 18, 2011	DS	DP	D-40	Aug 02, 2007
	5034394*PED	Jun 18, 2012				
	5047407	Nov 17, 2009	DS	DP U-257		
	5047407*PED	May 17, 2010				
	5089500	Jun 26, 2009		U-257		
	5089500*PED	Dec 26, 2009				
	5905082	May 18, 2016	DS	DP		
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS	DP U-257		
	6294540*PED	Nov 14, 2018				
ALBUTEROL SULFATE - PROAIR HFA						
021457 001					I-235	Feb 03, 2009
ALBUTEROL SULFATE - VENTOLIN HFA						
020983 001	6131566	Apr 14, 2015		DP U-716		
	6131566	Apr 14, 2015		DP U-589		
	6532955	Apr 14, 2015		DP U-716		
	6532955	Apr 14, 2015		DP U-590		
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D						
021762 001					NC	Apr 07, 2008
ALFUZOSIN HYDROCHLORIDE - UROXATRAL						
021287 001	4661491	May 27, 2007		U-706		
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL						
020364 006					NS	Apr 11, 2009
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL						
020364 007					NS	Apr 11, 2009
ANIDULAFUNGIN - ERAXIS						
021632 001	5965525	Oct 12, 2016	DS	DP U-540	NCE	Feb 17, 2011
	6384013	Mar 19, 2012	DS			
	6743777	Mar 19, 2012		DP U-540		
	6960564	Apr 12, 2021		DP U-540		
APREPITANT - EMEND						
021549 001	5145684	Jan 25, 2011		DP		
APREPITANT - EMEND						
021549 002	5145684	Jan 25, 2011		DP		
ARIPIPRAZOLE - ABILIFY						
021436 001					I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY						
021436 002					I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY						
021436 003					I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY						
021436 004					I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY						
021436 005					I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY						
021436 006					I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY						
021713 001	6977257	Apr 24, 2022	DS	DP	I-488	Mar 01, 2008
ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAINE						
022010 001					NP	Mar 30, 2009
AZELASTINE HYDROCHLORIDE - ASTELIN						
020114 001					D-102	Feb 17, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX					
021852 001	4866048	Dec 29, 2007	DS DP U-88	NC	Jan 09, 2009
	4866048	Dec 29, 2007	DS DP U-193		
	5763426	Jun 09, 2015	DS DP		
	6753013	Jan 27, 2020	DP U-88		
	6753013	Jan 27, 2020	DP U-193		
BIVALIRUDIN - ANGIOMAX					
020873 001				I-486	Nov 30, 2008
BORTEZOMIB - VELCADE					
021602 001				ODE	Mar 25, 2012
BRIMONIDINE TARTRATE - ALPHAGAN P					
021770 001	5424078	Jun 13, 2012	DP		
	5424078*PED	Dec 13, 2012			
	6562873	Jul 10, 2021	DP		
	6562873*PED	Jan 10, 2022			
	6627210	Jul 18, 2021	DP		
	6627210*PED	Jan 18, 2022			
	6641834	Jul 28, 2021	DP		
	6641834*PED	Jan 28, 2022			
	6673337	Jul 26, 2021	DP		
	6673337*PED	Jan 26, 2022			
BROMFENAC SODIUM - XIBROM					
021664 001				I-485	Jan 27, 2009
BUDESONIDE - PULMICORT RESPULES					
020929 001	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
BUDESONIDE - PULMICORT RESPULES					
020929 002	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
BUDESONIDE - RHINOCORT					
020746 001	6986904	Apr 29, 2017	DP U-699		
BUDESONIDE - RHINOCORT					
020746 002	6986904	Apr 29, 2017	DP U-699		
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)					
021823 001				M-52	Jan 24, 2009
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100					
021485 002	**>A>** 4963590	Nov 27, 2007	DP U-219		
	>A> 5112861	May 12, 2009	U-219		
	>A> 5135950	Oct 31, 2010	DS DP U-219		
	>A> 6500867	Jun 29, 2020	DP U-219		
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150					
021485 003	**>A>** 4963590	Nov 27, 2007	DP U-219		
	>A> 5112861	May 12, 2009	U-219		
	>A> 5135950	Oct 31, 2010	DS DP U-219		
	>A> 6500867	Jun 29, 2020	DP U-219		
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50					
021485 001	**>A>** 4963590	Nov 27, 2007	DP U-219		
	>A> 5112861	May 12, 2009	U-219		
	>A> 5135950	Oct 31, 2010	DS DP U-219		
	>A> 6500867	Jun 29, 2020	DP U-219		
CEFDITOREN PIVOXIL - SPECTRACEF					
021222 001	4839350	Apr 14, 2009	DS DP		
CETIRIZINE HYDROCHLORIDE - ZYRTEC					
019835 001	4525358	Jun 25, 2007	DS DP U-565		
	4525358*PED	Dec 25, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CETIRIZINE HYDROCHLORIDE - ZYRTEC								
019835 002		4525358	Jun 25, 2007	DS	DP	U-565		
		4525358*PED	Dec 25, 2007					
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR								
021150 001		7014867	Jun 10, 2022		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP								
020832 004	**>A>**	5690958	Sep 30, 2016		DP			
	>A>	6536975	Nov 10, 2020		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP								
020832 003	**>A>**	5538353	Aug 25, 2015		DP			
	>A>	5690958	Sep 30, 2016		DP			
	>A>	5752363	Apr 22, 2017		DP			
	>A>	5772346	Apr 22, 2017		DP			
	>A>	D386849	Nov 25, 2011		DP			
	>A>	D396911	Aug 11, 2012		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK								
021555 002		5690958	Sep 30, 2016		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
020832 002	**>A>**	6991393	Mar 14, 2023		DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT								
020832 005	**>A>**	5690958	Sep 30, 2016		DP			
	>A>	6536975	Nov 10, 2020		DP			
	>A>	6729786	Mar 14, 2023		DP			
	>A>	6991393	Jan 31, 2024		DP			
CICLOPIROX - LOPROX								
020519 001		7018656	Sep 05, 2018		DP			
		7026337	Apr 02, 2018			U-714		
CONIVAPTAN HYDROCHLORIDE - VAPRISOL								
021697 001		5723606	Mar 03, 2015	DS	DP	U-698		
DAPTOMYCIN - CUBICIN								
021572 001	**>A>**	RE39071	Jun 15, 2016	DS	DP	U-728		
DAPTOMYCIN - CUBICIN								
021572 002	**>A>**	RE39071	Jun 15, 2016	DS	DP	U-728		
DECITABINE - DACOGEN								
021790 001							**>A>** NCE	May 02, 2011
DESFLURANE - SUPRANE								
020118 001		5617906	Apr 08, 2014		DP			
DESLORATADINE - CLARINEX								
021165 001		4659716	Mar 31, 2007		DP	U-725		
		4659716	Mar 31, 2007		DP	U-427		
		4659716*PED	Oct 01, 2007			U-427		
DESLORATADINE - CLARINEX								
021300 001		4659716	Mar 31, 2007		DP	U-725		
		4659716	Mar 31, 2007		DP	U-611		
		4659716*PED	Oct 01, 2007					
DESLORATADINE - CLARINEX								
021312 001		4659716	Mar 31, 2007		DP	U-725		
		4659716	Mar 31, 2007		DP	U-427		
		4659716*PED	Oct 01, 2007			U-427		
	>A>	5607697	Jun 07, 2015		DP			
DESLORATADINE - CLARINEX								
021312 002		4659716	Mar 31, 2007		DP	U-725		
		4659716	Mar 31, 2007		DP	U-427		
		4659716*PED	Oct 01, 2007		DP			
	>A>	5607697	Jun 07, 2015		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR								
021605 001		4659716	Mar 31, 2007		DP	U-726		
		4659716	Mar 31, 2007		DP	U-644		
		4659716*PED	Oct 01, 2007					
		6979463	Mar 28, 2022		DP			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR								
021313 001		4659716	Mar 31, 2007		DP	U-707	NCE	Dec 21, 2006
		4659716*PED	Oct 01, 2007				NC	Mar 03, 2008
		6100274	Jul 07, 2019		DP		PED	Jun 21, 2007
	>A>	6100274*PED	Jan 07, 2020					
		6709676	Feb 18, 2021		DP	U-707		
DESMOPRESSIN ACETATE - DDAVP								
019955 001	>A>	7022340	Apr 30, 2023		DP			
DESMOPRESSIN ACETATE - DDAVP								
019955 002	>A>	7022340	Apr 30, 2023		DP			
DOCETAXEL - TAXOTERE								
020449 001		5750561	Jul 03, 2012		DP		I-490	Mar 22, 2009
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT								
021720 001		4895841	Nov 25, 2010	DS	DP	U-713		
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT								
021720 002		4895841	Nov 25, 2010	DS	DP	U-713		
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ								
021676 001		5569652	Oct 29, 2013			U-1	NP	Mar 16, 2009
		5798338	Jul 10, 2015		DP			
		6787531	Aug 31, 2020		DP			
		6933395	Aug 11, 2017		DP			
	>A>	6958326	Dec 20, 2021		DP			
		RE37564	Jun 30, 2014		DP			
		RE37838	Jun 30, 2014		DP			
		RE38253	Jun 30, 2014		DP			
EFAVIRENZ - SUSTIVA								
020972 001	>A>	5519021	May 21, 2013	DS	DP			
	>A>	5663169	Sep 02, 2014			U-257		
	>A>	5811423	Aug 07, 2012	DS	DP	U-256		
	>A>	6238695	Apr 06, 2019		DP			
EFAVIRENZ - SUSTIVA								
020972 002	>A>	5519021	May 21, 2013	DS	DP			
	>A>	5663169	Sep 02, 2014			U-257		
	>A>	5811423	Aug 07, 2012	DS	DP	U-256		
	>A>	6238695	Apr 06, 2019		DP			
EFAVIRENZ - SUSTIVA								
020972 003	>A>	5519021	May 21, 2013	DS	DP			
	>A>	5663169	Sep 02, 2014			U-257		
	>A>	5811423	Aug 07, 2012	DS	DP	U-256		
	>A>	6238695	Apr 06, 2019		DP			
EFAVIRENZ - SUSTIVA								
021360 002	>A>	5519021	May 21, 2013	DS	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE - EMTRIVA						
021500 001	**>A>** 5210085	May 11, 2010			**>A>** NCE	Jul 02, 2008
	>A> 5210085*PED	Nov 11, 2010			**>A>** PED	Jan 02, 2009
	>A> 5814639	Sep 29, 2015				
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Sep 29, 2015				
	>A> 5914331*PED	Mar 29, 2016				
	>A> 6642245	Nov 04, 2020		U-541		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS	DP		
	>A> 6703396*PED	Sep 09, 2021				
EMTRICITABINE - EMTRIVA						
021896 001	**>A>** 5210085	May 11, 2010		U-257	**>A>** NDF	Sep 27, 2008
	>A> 5210085*PED	Nov 11, 2010			**>A>** NCE	Jul 02, 2008
	>A> 5814639	Sep 29, 2015	DS	DP	**>A>** PED	Mar 27, 2009
	>A> 5814639*PED	Mar 29, 2016			**>A>** PED	Jan 02, 2009
	>A> 5914331	Sep 29, 2015	DS			
	>A> 5914331*PED	Mar 29, 2016				
	>A> 6642245	Nov 04, 2020		U-257		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS	DP		
	>A> 6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
021752 001	**>A>** 5210085	May 11, 2010		U-248	**>A>** NCE	Jul 02, 2008
	>A> 5210085	May 11, 2010		U-541	**>A>** PED	Jan 02, 2009
	>A> 5210085*PED	Nov 11, 2010				
	>A> 5814639	Sep 29, 2015	DS	DP		
	>A> 5814639*PED	Mar 29, 2016				
	>A> 5914331	Sep 29, 2015	DS	DP	U-248	
	>A> 5914331*PED	Mar 29, 2016				
	>A> 6642245	Nov 04, 2020		U-248		
	>A> 6642245	Nov 04, 2020		U-541		
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS	DP		
	>A> 6703396*PED	Sep 09, 2021				
ENTACAPONE - COMTAN						
020796 001	**>A>** 4963590	Nov 27, 2007		DP	U-219	
	>A> 5112861	May 12, 2009			U-219	
	>A> 5135950	Oct 31, 2010	DS	DP	U-219	
	>A> 6599530	Sep 14, 2018		DP	U-219	
EPLERENONE - INSPRA						
021437 001	4559332	Apr 09, 2007	DS	DP	U-537	
EPLERENONE - INSPRA						
021437 002	4559332	Apr 09, 2007	DS	DP	U-537	
EPLERENONE - INSPRA						
021437 003	4559332	Apr 09, 2007	DS	DP	U-537	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM - NEXIUM					
021153 001	4738974	Apr 19, 2007 DS	DP U-635	I-484	Nov 24, 2007
	4738974	Apr 19, 2007 DS	DP U-373	NPP	Apr 28, 2009
	4738974*PED	Oct 19, 2007	U-373		
	>A> 4786505	Apr 20, 2007	DP U-373		
	>A> 4786505	Apr 20, 2007	DP U-729		
	>A> 4853230	Apr 20, 2007	DP U-729		
	>A> 4853230	Apr 20, 2007	DP U-373		
	>A> 5690960	Nov 25, 2014	DP U-729		
	>A> 5690960	Nov 25, 2014	DP U-373		
	>A> 5714504	Feb 03, 2015	DP U-729		
	>A> 5714504	Feb 03, 2015	DP U-373		
	>A> 5877192	May 27, 2014	DP U-373		
	>A> 5877192	May 27, 2014	DP U-729		
	>A> 5900424	May 04, 2016 DS	U-729		
	>A> 5900424	May 04, 2016 DS	U-373		
	>A> 6369085	May 25, 2018 DS	DP U-729		
	>A> 6428810	Nov 03, 2019	DP U-469		
	>A> 6428810	Nov 03, 2019	DP U-729		
ESOMEPRAZOLE MAGNESIUM - NEXIUM					
021153 002	4738974	Apr 19, 2007 DS	DP U-635	I-484	Nov 24, 2007
	4738974	Apr 19, 2007 DS	DP U-373	NPP	Apr 28, 2009
	4738974*PED	Oct 19, 2007	U-373		
	>A> 4786505	Apr 20, 2007	DP U-373		
	>A> 4786505	Apr 20, 2007	DP U-729		
	>A> 4853230	Apr 20, 2007	DP U-729		
	>A> 4853230	Apr 20, 2007	DP U-373		
	>A> 5690960	Nov 25, 2014	DP U-729		
	>A> 5690960	Nov 25, 2014	DP U-373		
	>A> 5714504	Feb 03, 2015	DP U-729		
	>A> 5714504	Feb 03, 2015	DP U-373		
	>A> 5877192	May 27, 2014	DP U-373		
	>A> 5877192	May 27, 2014	DP U-729		
	>A> 5900424	May 04, 2016 DS	U-729		
	>A> 5900424	May 04, 2016 DS	U-373		
	>A> 6369085	May 25, 2018 DS	DP U-729		
	>A> 6428810	Nov 03, 2019	DP U-469		
	>A> 6428810	Nov 03, 2019	DP U-729		
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE					
021840 001				**>A>** NP	May 25, 2009
ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA					
021180 001	5876746	Nov 20, 2015	DP U-514		
ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35					
021490 001	6667050	Apr 06, 2019	DP U-1		
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE					
021871 001	5552394	Jul 22, 2014	U-1	NP	Feb 17, 2009
EXEMESTANE - AROMASIN					
020753 001				**>A>** I-495	Oct 05, 2008
EZETIMIBE - ZETIA					
021445 001	**>A>** 7030106	Jan 25, 2022	DP	**>A>** I-493	May 23, 2009
FENOFIBRATE - FENOFIBRATE					
076433 001				PC	May 22, 2006
FENOFIBRATE - FENOFIBRATE					
076433 002				PC	May 22, 2006
FENOFIBRATE - LIPOFEN					
021612 001	5545628	Jan 10, 2015	U-701		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - LIPOFEN					
021612 002	5545628	Jan 10, 2015	U-701		
FENOFIBRATE - LIPOFEN					
021612 003	5545628	Jan 10, 2015	U-701		
FENOFIBRATE - TRICOR					
021656 001	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
FENOFIBRATE - TRICOR					
021656 002	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
FENTANYL HYDROCHLORIDE - IONSYS					
021338 001				**>A>** NDF	May 22, 2009
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR					
021704 001	RE39069	May 29, 2018	DP		
FLUNISOLIDE - AEROSPAN HFA					
021247 001				NP	Jan 27, 2009
FLUOCINOLONE ACETONIDE - RETISERT					
021737 001	6217895	Mar 22, 2019	DP U-708		
	6548078	Mar 22, 2019	DP U-708		
FLUOCINONIDE - VANOS					
021758 001				I-487	Mar 02, 2009
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY					
021235 001	RE39030	May 29, 2017	DP U-397		
	RE39030	May 29, 2017	DP U-396		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 001	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 002	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 003	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50					
021077 001	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50					
021077 002	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE			PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50							
021077 003	4992474	Feb	12,	2008	U-211		
	4992474*PED	Aug	12,	2008	U-211		
	5126375	Feb	12,	2008			
	5126375*PED	Aug	12,	2008			
	5225445	Feb	12,	2008	U-211		
	5225445*PED	Aug	12,	2008	U-211		
	6536427	Mar	01,	2011	DP		
	6536427*PED	Sep	01,	2011			
FROVATRIPTAN SUCCINATE - FROVA							
021006 001	5464864	Nov	07,	2015	U-436		
FULVESTRANT - FASLODEX							
021344 001	4659516	Oct	01,	2006			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 001						**>A>** NDF	Apr 01, 2008
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 002						**>A>** NDF	Apr 01, 2008
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 003						**>A>** NDF	Apr 01, 2008
GLIMEPIRIDE - AMARYL							
020496 001						M-54	Nov 28, 2008
						PED	May 28, 2009
GLIMEPIRIDE - AMARYL							
020496 002						M-54	Nov 28, 2008
						PED	May 28, 2009
GLIMEPIRIDE - AMARYL							
020496 003						M-54	Nov 28, 2008
						PED	May 28, 2009
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
021700 001	5002953	Sep	17,	2011	DS DP U-690		
	5002953*PED	Mar	17,	2012			
	5741803	Apr	21,	2015	DS DP U-690		
	5741803*PED	Oct	21,	2015			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
021700 002	5002953	Sep	17,	2011	DS DP U-690		
	5002953*PED	Mar	17,	2012			
	5741803	Apr	21,	2015	DS DP U-690		
	5741803*PED	Oct	21,	2015			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
021700 003	5002953	Sep	17,	2011	DS DP U-690		
	5002953*PED	Mar	17,	2012			
	5741803	Apr	21,	2015	DS DP U-690		
	5741803*PED	Oct	21,	2015			
HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT							
021859 001						NCE	Dec 02, 2010
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT							
020818 004						NS	Apr 28, 2009
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT							
020818 005						NS	Apr 28, 2009
IBANDRONATE SODIUM - BONIVA							
021455 001	4927814	Jul	09,	2007	DS DP U-642		
	6143326	Apr	21,	2017	U-642		
IBANDRONATE SODIUM - BONIVA							
021858 001	4927814	Jul	09,	2007	DS DP U-700	NDF	Jan 06, 2009
						NCE	May 16, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBUPROFEN LYSINE - NEOPROFEN					
021903 001				NE	Apr 13, 2009
				ODE	Apr 13, 2013
IMATINIB MESYLATE - GLEEVEC					
021335 001	>A> 5521184	Jan 04, 2015		>A> I-392	May 20, 2006
	>A> 5521184*PED	Jul 04, 2015		>A> I-376	Dec 20, 2005
	>A> 6894051	May 23, 2019	DS DP U-649	>A> NCE	May 10, 2006
	>A> 6894051*PED	Nov 23, 2019		>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
IMATINIB MESYLATE - GLEEVEC					
021335 002	>A> 5521184	Jan 04, 2015		>A> I-392	May 20, 2006
	>A> 5521184*PED	Jul 04, 2015		>A> I-376	Dec 20, 2005
	>A> 6894051	May 23, 2019	DS DP U-649	>A> NCE	May 10, 2006
	>A> 6894051*PED	Nov 23, 2019		>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
IMATINIB MESYLATE - GLEEVEC					
021588 001	>A> 5521184	Jan 04, 2015		>A> I-392	May 20, 2006
	>A> 5521184*PED	Jul 04, 2015		>A> I-376	Dec 20, 2005
	>A> 6894051	May 23, 2019	DS DP U-649	>A> NCE	May 10, 2006
	>A> 6894051*PED	Nov 23, 2019		>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
IMATINIB MESYLATE - GLEEVEC					
021588 002	>A> 5521184	Jan 04, 2015		>A> I-392	May 20, 2006
	>A> 5521184*PED	Jul 04, 2015		>A> I-376	Dec 20, 2005
	>A> 6894051	May 23, 2019	DS DP U-649	>A> NCE	May 10, 2006
	>A> 6894051*PED	Nov 23, 2019		>A> ODE	Feb 01, 2009
				>A> ODE	May 10, 2008
				>A> PED	Aug 01, 2009
				>A> PED	Nov 10, 2008
				>A> PED	Nov 20, 2006
				>A> PED	Nov 10, 2006
				>A> PED	Jun 20, 2006
INSULIN DETEMIR RECOMBINANT - LEVEMIR					
021536 001				I-489	Oct 19, 2008
INSULIN RECOMBINANT HUMAN - EXUBERA					
021868 001	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014	U-704		
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019	U-704		
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019	U-704		
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014	U-704		
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - EXUBERA						
021868 002	5740794	Apr 21, 2015	DP		NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
	RE37872	Feb 12, 2010	DP			
	RE38385	Feb 12, 2010	DP			
IPRATROPIUM BROMIDE - ATROVENT HFA						
021527 001	6983743	May 26, 2020	DP			
LANSOPRAZOLE - PREVACID						
020406 001	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
020406 002	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021281 001	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021281 002	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021428 001	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021428 002	6749864	Feb 13, 2007	DP			
LANTHANUM CARBONATE - FOSRENOL						
021468 003	5968976	Mar 19, 2016	DP	U-613		
LANTHANUM CARBONATE - FOSRENOL						
021468 004	5968976	Mar 19, 2016	DP	U-613		
LENALIDOMIDE - REVLIMID						
021880 001	5635517	Jul 24, 2016	DS		ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
LENALIDOMIDE - REVLIMID						
021880 002	5635517	Jul 24, 2016	DS		ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
LEVETIRACETAM - KEPPRA						
021035 004					NPP	Jun 21, 2008
LIDOCAINE; TETRACAINE - SYNERA						
021623 001					>A> NC	Jun 23, 2008

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES			EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA								
021906 001		5541206	Jul 30, 2013	DS	DP	U-688		
		5541206*PED	Jan 30, 2014					
		5635523	Jun 03, 2014			U-688		
		5635523*PED	Dec 03, 2014					
		5648497	Jul 15, 2014	DS	DP			
		5648497*PED	Jan 15, 2015					
		5674882	Oct 07, 2014			U-688		
		5674882*PED	Apr 07, 2015					
		5846987	Dec 29, 2012			U-688		
		5846987*PED	Jun 29, 2013					
		5886036	Dec 29, 2012		DP			
		5886036*PED	Jun 29, 2013					
		6037157	Jun 26, 2016			U-688		
		6037157*PED	Dec 26, 2016					
		6703403	Jun 26, 2016			U-688		
		6703403*PED	Dec 26, 2016					
LOVASTATIN; NIACIN - ADVICOR								
021249 001		7011848	Sep 20, 2013			U-712		
LOVASTATIN; NIACIN - ADVICOR								
021249 002		7011848	Sep 20, 2013			U-712		
LOVASTATIN; NIACIN - ADVICOR								
021249 003		7011848	Sep 20, 2013			U-712		
LUBIPROSTONE - AMITIZA								
021908 001		5284858	Feb 08, 2011	DS	DP		NCE	Jan 31, 2011
		5317032	May 31, 2011	DS	DP	U-717		
		6414016	Sep 05, 2020	DS	DP	U-717		
		6583174	Oct 16, 2020	DS	DP			
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID								
021850 001	**>A>**	6489346	Jul 16, 2016	DS	DP	U-623		
	>A>	6489346	Jul 16, 2016	DS	DP	U-588		
		6645988	Jul 16, 2016	DS	DP	U-623		
		6645988	Jul 16, 2016	DS	DP	U-588		
	>A>	6699885	Jul 16, 2016			U-623		
	>A>	6699885	Jul 16, 2016			U-588		
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID								
021850 002	**>A>**	6489346	Jul 16, 2016	DS	DP	U-623		
	>A>	6489346	Jul 16, 2016	DS	DP	U-588		
		6645988	Jul 16, 2016	DS	DP	U-623		
		6645988	Jul 16, 2016	DS	DP	U-588		
	>A>	6699885	Jul 16, 2016			U-623		
	>A>	6699885	Jul 16, 2016			U-588		
MECASERMIN RINFABATE RECOMBINANT - IPLEX								
021884 001		5200509	Apr 06, 2010	DS				
		5681818	Oct 28, 2014			U-697		
MELOXICAM - MOBIC								
020938 001							ODE	Aug 11, 2012
							PED	Feb 11, 2013
MELOXICAM - MOBIC								
020938 002							ODE	Aug 11, 2012
							PED	Feb 11, 2013
MELOXICAM - MOBIC								
021530 001							I-469	Aug 11, 2008
							ODE	Aug 11, 2012
							PED	Feb 11, 2013
							PED	Feb 11, 2009
MEQUINOL; TRETINOIN - SOLAGE								
020922 001		5194247	Dec 10, 2013		DP	U-294		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET					
021410 001	**>A>** 5002953	Sep 17, 2011	DS DP U-690	**>A>** I-494	May 19, 2009
	>A> 5002953	Sep 17, 2011	DS DP U-734		
	>A> 5002953	Sep 17, 2011	DS DP U-691		
	>A> 5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DP U-734		
	>A> 5741803	Apr 21, 2015	DP U-493		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET					
021410 002	**>A>** 5002953	Sep 17, 2011	DS DP U-690	**>A>** I-494	May 19, 2009
	>A> 5002953	Sep 17, 2011	DS DP U-734		
	>A> 5002953	Sep 17, 2011	DS DP U-691		
	>A> 5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DP U-734		
	>A> 5741803	Apr 21, 2015	DP U-493		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET					
021410 003	**>A>** 5002953	Sep 17, 2011	DS DP U-691	**>A>** I-494	May 19, 2009
	>A> 5002953	Sep 17, 2011	DS DP U-734		
	>A> 5002953	Sep 17, 2011	DS DP U-690		
	>A> 5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DP U-734		
	>A> 5741803	Apr 21, 2015	DP U-493		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET					
021410 004	**>A>** 5002953	Sep 17, 2011	DS DP U-691	**>A>** I-494	May 19, 2009
	>A> 5002953	Sep 17, 2011	DS DP U-734		
	>A> 5002953	Sep 17, 2011	DS DP U-690		
	>A> 5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DP U-734		
	>A> 5741803	Apr 21, 2015	DP U-493		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET					
021410 005	**>A>** 5002953	Sep 17, 2011	DS DP U-690	**>A>** I-494	May 19, 2009
	>A> 5002953	Sep 17, 2011	DS DP U-734		
	>A> 5002953	Sep 17, 2011	DS DP U-691		
	>A> 5002953	Sep 17, 2011	DS DP U-493		
	>A> 5741803	Apr 21, 2015	DP U-734		
	>A> 5741803	Apr 21, 2015	DP U-493		
METHYLPHENIDATE - DAYTRANA					
021514 001	**>A>** 5958446	Dec 12, 2012	DP	**>A>** NDF	Apr 06, 2009
	>A> 6210705	Sep 30, 2018	DP U-727		
	>A> 6348211	Sep 30, 2018	DP U-727		
METHYLPHENIDATE - DAYTRANA					
021514 002	**>A>** 5958446	Dec 12, 2012	DP	**>A>** NDF	Apr 06, 2009
	>A> 6210705	Sep 30, 2018	DP U-727		
	>A> 6348211	Sep 30, 2018	DP U-727		
METHYLPHENIDATE - DAYTRANA					
021514 003	**>A>** 5958446	Dec 12, 2012	DP	**>A>** NDF	Apr 06, 2009
	>A> 6210705	Sep 30, 2018	DP U-727		
	>A> 6348211	Sep 30, 2018	DP U-727		
METHYLPHENIDATE - DAYTRANA					
021514 004	**>A>** 5958446	Dec 12, 2012	DP	**>A>** NDF	Apr 06, 2009
	>A> 6210705	Sep 30, 2018	DP U-727		
	>A> 6348211	Sep 30, 2018	DP U-727		
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION					
021026 001	4911932	Mar 27, 2007	DP U-718	NP	Feb 16, 2009
MINOXIDIL - MEN'S ROGAINE					
021812 001	6946120	Apr 20, 2019	DP U-702	NDF	Jan 20, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MODAFINIL - PROVIGIL					
020717 001	4927855	May 22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov 22, 2007		ODE	Dec 24, 2005
	RE37516	Oct 06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr 06, 2015		PED	Jun 24, 2006
MODAFINIL - PROVIGIL					
020717 002	4927855	May 22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov 22, 2007		ODE	Dec 24, 2005
	RE37516	Oct 06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr 06, 2015		PED	Jun 24, 2006
MORPHINE SULFATE - KADIAN					
020616 004	5378474	Mar 23, 2010			
MORPHINE SULFATE - KADIAN					
020616 005	5202128	Apr 13, 2010			
	5378474	Mar 23, 2010			
MOXIFLOXACIN HYDROCHLORIDE - AVELOX					
021085 001	4990517	Dec 08, 2011	DS DP	U-298	
	6610327	Oct 29, 2019	DP	U-298	
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
021277 001	4990517	Dec 08, 2011	DS DP	U-298	
	6548079	Jul 25, 2020	DP	U-298	
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX					
021598 001	4990517	Dec 08, 2011	DS DP	U-709	
	4990517*PED	Jun 08, 2012			
NALTREXONE - VIVITROL					
021897 001	**>A>** 5792477	May 02, 2017	DP	NDF	Apr 13, 2009
	>A> 5916598	May 02, 2017	DP		
	>A> 6110503	May 02, 2017	DP		
	>A> 6194006	Dec 30, 2018	DP		
	>A> 6264987	May 19, 2020	DP		
	>A> 6331317	Nov 12, 2019	DP		
	>A> 6379703	Dec 30, 2018	DP		
	>A> 6379704	May 19, 2020	DP		
	>A> 6395304	Nov 12, 2019	DP		
	>A> 6403114	May 02, 2017	DP		
	>A> 6495164	May 25, 2020	DP		
	>A> 6495166	Nov 12, 2019	DP		
	>A> 6534092	May 19, 2020	DP		
	>A> 6537586	Nov 12, 2019	DP		
	>A> 6596316	Dec 30, 2018	DP		
	>A> 6667061	May 25, 2020	DP		
	>A> 6713090	Nov 12, 2019	DP		
	>A> 6939033	Nov 12, 2019	DP		
NELARABINE - ARRANON					
021877 001	5747472	Feb 20, 2013	U-696		
	5747472	Feb 20, 2013	U-695		
	5747472	Feb 20, 2013	U-689		
	5821236	Feb 20, 2013	U-695		
NIACIN - NIASPAN					
020381 001	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN					
020381 002	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN					
020381 003	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN					
020381 004	7011848	Sep 20, 2013	U-712		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN TITRATION STARTER PACK						
020381 005		7011848	Sep 20, 2013	U-712		
NICOTINE POLACRILEX - NICOTINE POLACRILEX						
077007 001					PC	Aug 21, 2006
NICOTINE POLACRILEX - NICOTINE POLACRILEX						
077007 002					PC	Aug 21, 2006
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 001		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 002		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 003		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 004		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 005		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
021008 001	>A>	5538739	Jul 23, 2013	DP	>A> M-55	May 10, 2009
		5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	>A>	5639480	Jun 17, 2014	DP	>A> PED	Nov 10, 2009
		5639480*PED	Dec 17, 2014		PED	May 25, 2006
		5688530	Nov 18, 2014	U-268		
		5688530*PED	May 18, 2015			
	>A>	5922338	Jul 13, 2016	DP		
		5922338*PED	Jan 13, 2017			
	>A>	5922682	Jul 13, 2016	DP		
		5922682*PED	Jan 13, 2017			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
021008 002		5538739	Jul 23, 2013		>A> M-55	May 10, 2009
		5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	>A>	5639480	Jun 17, 2014	DP	>A> PED	Nov 10, 2009
		5639480*PED	Dec 17, 2014		PED	May 25, 2006
		5688530	Nov 18, 2014	U-268		
		5688530*PED	May 18, 2015			
	>A>	5922338	Jul 13, 2016	DP		
		5922338*PED	Jan 13, 2017			
	>A>	5922682	Jul 13, 2016	DP		
		5922682*PED	Jan 13, 2017			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
021008 003		5538739	Jul 23, 2013		>A> M-55	May 25, 2009
		5538739*PED	Jan 23, 2014		ODE	Nov 25, 2005
	>A>	5639480	Jun 17, 2014	DP	>A> PED	Nov 25, 2009
		5639480*PED	Dec 17, 2014		PED	May 25, 2006
		5688530	Nov 18, 2014	U-268		
		5688530*PED	May 18, 2015			
	>A>	5922338	Jul 13, 2016	DP		
		5922338*PED	Jan 13, 2017			
	>A>	5922682	Jul 13, 2016	DP		
		5922682*PED	Jan 13, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
021849 001		6489346	Jul 16, 2016	DS	DP U-588		
		6645988	Jul 16, 2016	DS	DP		
		6699885	Jul 16, 2016		U-588		
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
021849 002		6489346	Jul 16, 2016	DS	DP U-623		
		6489346	Jul 16, 2016	DS	DP U-588		
		6645988	Jul 16, 2016	DS	DP		
		6699885	Jul 16, 2016		U-623		
		6699885	Jul 16, 2016		U-588		
OXALIPLATIN - ELOXATIN							
021492 001		5420319	Aug 09, 2016	DS			
OXALIPLATIN - ELOXATIN							
021492 002		5420319	Aug 09, 2016	DS			
OXALIPLATIN - ELOXATIN							
021759 001		5420319	Aug 08, 2016	DS			
OXALIPLATIN - ELOXATIN							
021759 002		5420319	Aug 08, 2016	DS			
OXCARBAZEPINE - TRILEPTAL							
021014 001		7037525	Feb 12, 2018		U-724		
OXCARBAZEPINE - TRILEPTAL							
021014 002		7037525	Feb 12, 2018		U-724		
OXCARBAZEPINE - TRILEPTAL							
021014 003		7037525	Feb 12, 2018		U-724		
OXCARBAZEPINE - TRILEPTAL							
021285 001	**>A>**	7037525	Feb 12, 2018		U-724		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
020667 001		4843086	Jun 27, 2006		U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
020667 002		4843086	Jun 27, 2006		U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
020667 003		4843086	Jun 27, 2006		U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
020667 004		4843086	Jun 27, 2006		U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
020667 005		4843086	Jun 27, 2006		U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
020667 006		4843086	Jun 27, 2006		U-231		
PRAVASTATIN SODIUM - PRAVASTATIN SODIUM							
076056 001						PC	Oct 21, 2006
PRAVASTATIN SODIUM - PRAVASTATIN SODIUM							
076056 002						PC	Oct 21, 2006
PRAVASTATIN SODIUM - PRAVASTATIN SODIUM							
076056 003						PC	Oct 21, 2006
QUETIAPINE FUMARATE - SEROQUEL							
020639 006		4879288	Sep 26, 2011	DS	DP U-550		
QUETIAPINE FUMARATE - SEROQUEL							
020639 007		4879288	Sep 26, 2011	DS	DP U-550		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RALOXIFENE HYDROCHLORIDE - EVISTA							
020815 001		RE38968	Jul 28, 2012		U-662		
		RE38968	Jul 28, 2012		U-657		
		RE39049	Jul 28, 2012		U-662		
		RE39049	Jul 28, 2012		U-657		
		RE39050	Mar 02, 2014		U-662		
		RE39050	Mar 02, 2014		U-657		
RAMIPRIL - ALTACE							
019901 001	**>A>**	5061722	Oct 19, 2008				
RANOLAZINE - RANEXA							
021526 002	**>A>**	4567264	May 18, 2007	DS		NCE	Jan 27, 2011
		6303607	May 27, 2019		U-705		
		6369062	May 27, 2019	DP			
		6479496	May 27, 2019		U-705		
		6503911	May 27, 2019	DP			
		6525057	May 27, 2019		U-705		
		6562826	May 27, 2019		U-705		
		6617328	May 27, 2019	DP			
		6620814	May 27, 2019		U-705		
		6852724	May 27, 2019		U-705		
		6864258	May 27, 2019		U-705		
RASAGILINE MESYLATE - AZILECT							
021641 001						**>A>** NCE	May 16, 2011
RASAGILINE MESYLATE - AZILECT							
021641 002						**>A>** NCE	May 16, 2011
RIFAXIMIN - XIFAXAN							
021361 001	**>A>**	7045620	May 22, 2024	DS			
RISEDRONATE SODIUM - ACTONEL							
020835 001						M-52	Jan 24, 2009
RISEDRONATE SODIUM - ACTONEL							
020835 002						M-52	Jan 24, 2009
RISEDRONATE SODIUM - ACTONEL							
020835 003						M-52	Jan 24, 2009
RIVASTIGMINE TARTRATE - EXELON							
020823 003	**>A>**	4948807	Aug 14, 2012	DS	U-322		
RIVASTIGMINE TARTRATE - EXELON							
020823 004	**>A>**	4948807	Aug 14, 2012	DS	U-322		
RIVASTIGMINE TARTRATE - EXELON							
020823 005	**>A>**	4948807	Aug 14, 2012	DS	U-322		
RIVASTIGMINE TARTRATE - EXELON							
020823 006	**>A>**	4948807	Aug 14, 2012	DS	U-322		
RIVASTIGMINE TARTRATE - EXELON							
021025 001	**>A>**	4948807	Aug 14, 2012	DS	U-322		
ROCURONIUM BROMIDE - ZEMURON							
020214 003		4894369	Apr 13, 2008				
SALMETEROL XINAFOATE - SEREVENT							
020236 001		4992474	Feb 12, 2008				
		4992474*PED	Aug 12, 2008				
		5126375	Feb 12, 2008				
		5126375*PED	Aug 12, 2008				
		5225445	Feb 12, 2008		U-182		
		5225445*PED	Aug 12, 2008				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SALMETEROL XINAFOATE - SEREVENT							
020692 001		4992474	Feb 12, 2008				
		4992474*PED	Aug 12, 2008				
		5126375	Feb 12, 2008				
		5126375*PED	Aug 12, 2008				
		5225445	Feb 12, 2008			U-211	
		5225445*PED	Aug 12, 2008				
SELEGILINE - EMSAM							
021336 001		RE34579	Aug 18, 2007	DS	DP	U-711 NDF	Feb 27, 2009
SELEGILINE - EMSAM							
021336 002		RE34579	Aug 18, 2007	DS	DP	U-711 NDF	Feb 27, 2009
SELEGILINE - EMSAM							
021336 003		RE34579	Aug 18, 2007	DS	DP	U-711 NDF	Feb 27, 2009
SEVELAMER HYDROCHLORIDE - RENAGEL							
021179 001		7014846	Aug 11, 2013		DP	U-246	
SEVELAMER HYDROCHLORIDE - RENAGEL							
021179 002		7014846	Aug 11, 2013		DP	U-246	
SIMVASTATIN - ZOCOR							
019766 001	>A>	RE36481 ***	Jul 10, 2007			U-300	
	>A>	RE36481*PED	Jan 10, 2008			U-300	
	>A>	RE36520 ***	May 26, 2009			U-300	
	>A>	RE36520*PED	Nov 26, 2009			U-300	
SIMVASTATIN - ZOCOR							
019766 002	>A>	RE36481 ***	Jul 10, 2007			U-300	
	>A>	RE36481*PED	Jan 10, 2008			U-300	
	>A>	RE36520 ***	May 26, 2009			U-300	
	>A>	RE36520*PED	Nov 26, 2009			U-300	
SIMVASTATIN - ZOCOR							
019766 003	>A>	RE36481 ***	Jul 10, 2007			U-300	
	>A>	RE36481*PED	Jan 10, 2008			U-300	
	>A>	RE36520 ***	May 26, 2009			U-300	
	>A>	RE36520*PED	Nov 26, 2009			U-300	
SIMVASTATIN - ZOCOR							
019766 004	>A>	RE36481 ***	Jul 10, 2007			U-300	
	>A>	RE36481*PED	Jan 10, 2008			U-300	
	>A>	RE36520 ***	May 26, 2009			U-300	
	>A>	RE36520*PED	Nov 26, 2009			U-300	
SIMVASTATIN - ZOCOR							
019766 005	>A>	RE36481 ***	Jul 10, 2007			U-300	
	>A>	RE36481*PED	Jan 10, 2008			U-300	
	>A>	RE36520 ***	May 26, 2009			U-300	
	>A>	RE36520*PED	Nov 26, 2009			U-300	
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP							
021892 001		5616346	May 18, 2013		DP	U-715 NP	Mar 16, 2009
SOMATROPIN RECOMBINANT - GENOTROPIN							
020280 006	>A>	4968299	Jun 28, 2008		DP	>A> I-496	Apr 27, 2009
SOMATROPIN RECOMBINANT - GENOTROPIN							
020280 007	>A>	4968299	Jun 28, 2008		DP	>A> I-496	Apr 27, 2009
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 001	>A>	5435076	Apr 16, 2013		DP	>A> I-496	Apr 27, 2009
	>A>	5716338	Feb 10, 2015		DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE							
020280 002	>A>	5435076	Apr 16, 2013		DP	>A> I-496	Apr 27, 2009
	>A>	5716338	Feb 10, 2015		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 003	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 004				**>A>** I-496	Apr 27, 2009
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 005	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 008	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 009	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 010	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 011	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 012	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE					
020280 013	**>A>** 5435076	Apr 16, 2013	DP	**>A>** I-496	Apr 27, 2009
	>A> 5716338	Feb 10, 2015	DP		
SOMATROPIN RECOMBINANT - OMNITROPE					
021426 001				**>A>** NP	May 30, 2009
SOMATROPIN RECOMBINANT - OMNITROPE					
021426 002				**>A>** NP	May 30, 2009
SORAFENIB TOSYLATE - NEXAVAR					
021923 001				ODE	Dec 20, 2012
SUNITINIB MALATE - SUTENT					
021938 001	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011
SUNITINIB MALATE - SUTENT					
021938 002	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011
SUNITINIB MALATE - SUTENT					
021938 003	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011
TACROLIMUS - PROGRAF					
050708 001				ODE	Mar 29, 2013
TACROLIMUS - PROGRAF					
050708 002				ODE	Mar 29, 2013
TACROLIMUS - PROGRAF					
050708 003				ODE	Mar 29, 2013
TACROLIMUS - PROGRAF					
050709 001				ODE	Mar 29, 2013
TERIPARATIDE RECOMBINANT HUMAN - FORTEO					
021318 001	6977077	Aug 19, 2019	U-597		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID					
020785 001	>A> 5629327	Mar 01, 2013	U-731		
	>A> 6045501	Aug 28, 2018	U-731		
	>A> 6045501	Aug 28, 2018	U-371		
	>A> 6235756	Mar 01, 2013	U-731		
	>A> 6315720	Oct 23, 2020	U-442		
	>A> 6315720	Oct 23, 2020	U-731		
	>A> 6561976	Aug 28, 2018	U-731		
	>A> 6561976	Aug 28, 2018	U-371		
	>A> 6561977	Oct 23, 2020	U-371		
	>A> 6561977	Oct 23, 2020	U-731		
	>A> 6755784	Sep 23, 2020	U-731		
	>A> 6755784	Sep 23, 2020	U-371		
	>A> 6869399	Oct 23, 2020	U-371		
	>A> 6869399	Oct 23, 2020	U-732		
	>A> 6869399	Oct 23, 2020	U-733		
	>A> 6869399	Oct 23, 2020	U-731		
	>A> 6908432	Aug 28, 2018	U-371		
	>A> 6908432	Aug 28, 2018	U-731		
THALIDOMIDE - THALOMID					
020785 002	>A> 5629327	Mar 01, 2013	U-731		
	>A> 6045501	Aug 28, 2018	U-731		
	>A> 6045501	Aug 28, 2018	U-371		
	>A> 6235756	Mar 01, 2013	U-731		
	>A> 6315720	Oct 23, 2020	U-442		
	>A> 6315720	Oct 23, 2020	U-731		
	>A> 6561976	Aug 28, 2018	U-731		
	>A> 6561976	Aug 28, 2018	U-371		
	>A> 6561977	Oct 23, 2020	U-371		
	>A> 6561977	Oct 23, 2020	U-731		
	>A> 6755784	Sep 23, 2020	U-731		
	>A> 6755784	Sep 23, 2020	U-371		
	>A> 6869399	Oct 23, 2020	U-371		
	>A> 6869399	Oct 23, 2020	U-733		
	>A> 6869399	Oct 23, 2020	U-732		
	>A> 6869399	Oct 23, 2020	U-731		
	>A> 6908432	Aug 28, 2018	U-371		
	>A> 6908432	Aug 28, 2018	U-731		
THALIDOMIDE - THALOMID					
020785 003	>A> 5629327	Mar 01, 2013	U-731		
	>A> 6045501	Aug 28, 2018	U-731		
	>A> 6045501	Aug 28, 2018	U-371		
	>A> 6235756	Mar 01, 2013	U-731		
	>A> 6315720	Oct 23, 2020	U-442		
	>A> 6315720	Oct 23, 2020	U-731		
	>A> 6561976	Aug 28, 2018	U-731		
	>A> 6561976	Aug 28, 2018	U-371		
	>A> 6561977	Oct 23, 2020	U-371		
	>A> 6561977	Oct 23, 2020	U-731		
	>A> 6755784	Sep 23, 2020	U-731		
	>A> 6755784	Sep 23, 2020	U-371		
	>A> 6869399	Oct 23, 2020	U-371		
	>A> 6869399	Oct 23, 2020	U-732		
	>A> 6869399	Oct 23, 2020	U-733		
	>A> 6869399	Oct 23, 2020	U-731		
	>A> 6908432	Aug 28, 2018	U-371		
	>A> 6908432	Aug 28, 2018	U-731		
THYROTROPIN ALFA - THYROGEN					
020898 001					

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)		EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA									
021395 001		RE38912	Oct 11, 2021		DP				
TOPIRAMATE - TOPAMAX									
020505 001		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX									
020505 002		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX									
020505 003		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX									
020505 004		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX									
020505 005		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX									
020505 006		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX SPRINKLE									
020844 001		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX SPRINKLE									
020844 002		7018983	Oct 13, 2015			U-723			
TOPIRAMATE - TOPAMAX SPRINKLE									
020844 003		7018983	Oct 13, 2015			U-723			
TREPROSTINIL SODIUM - REMODULIN									
021272 001		5153222	Oct 06, 2014			U-455			
TREPROSTINIL SODIUM - REMODULIN									
021272 002		5153222	Oct 06, 2014			U-455			
TREPROSTINIL SODIUM - REMODULIN									
021272 003		5153222	Oct 06, 2014			U-455			
TREPROSTINIL SODIUM - REMODULIN									
021272 004		5153222	Oct 06, 2014			U-455			
VARENICLINE TARTRATE - CHANTIX									
021928 001							**>A>** NCE		May 10, 2011
VARENICLINE TARTRATE - CHANTIX									
021928 002							**>A>** NCE		May 10, 2011
ZANAMIVIR - RELENZA									
021036 001		5648379	Jul 15, 2014			U-722		I-491	Mar 29, 2009
		5648379	Jul 15, 2014			U-721			
		5648379	Jul 15, 2014			U-274			
		6294572	Dec 15, 2014	DS	DP				
ZIPRASIDONE HYDROCHLORIDE - GEODON									
020825 001	**>A>**	4831031	Mar 02, 2012	DS	DP	U-720	**>A>** I-492		Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON									
020825 002	**>A>**	4831031	Mar 02, 2012	DS	DP	U-720	**>A>** I-492		Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON									
020825 003	**>A>**	4831031	Mar 02, 2012	DS	DP	U-720	**>A>** I-492		Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON									
020825 004	**>A>**	4831031	Mar 02, 2012	DS	DP	U-720	**>A>** I-492		Aug 19, 2007
ZIPRASIDONE HYDROCHLORIDE - GEODON									
021483 001	**>A>**	4831031	Mar 02, 2012	DS	DP	U-720	**>A>** I-492		Aug 19, 2007
		5312925	Sep 01, 2012	DS	DP	U-720			
		6150366	May 27, 2019		DP	U-719			
		6245766	Dec 18, 2018			U-601			
ZIPRASIDONE MESYLATE - GEODON									
020919 001	**>A>**	4831031	Mar 02, 2012	DS	DP	U-720			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLEDRONIC ACID - ZOMETA					
021223 001	4939130	Sep 02, 2012	DS DP U-53		
ZOLEDRONIC ACID - ZOMETA					
021223 002	4939130	Sep 02, 2012	DS DP U-53		

Footnotes:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.
5. *** U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in Ranbaxy Labs. v. Leavitt, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm